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Abstract 
 
The insulin-like growth factor (IGF) axis comprises two growth factors (IGF-I and IGF-II), two 
cell surface receptors (IGF1R and IGF2R), six high affinity soluble IGF binding proteins 
(IGFBP1-6) and various families of IGFBP proteases. The IGF axis acts co-ordinately to 
control several cellular processes including mitogenesis, apoptosis, cell migration and 
differentiation. In this latter respect the IGFs are the most abundant growth factors present in 
bone matrix and the IGF axis is believed to play an important role in the differentiation of 
osteoblast precursors and also to control bone accretion and resorption which occurs 
throughout adult life. There is much interest in the use of mesenchymal stem cells (MSCs) 
as a resource for tissue engineering approaches in the restoration of bone and other hard 
tissue lesions. As such a thorough knowledge of the effects of the IGF axis on osteogenic 
differentiation is essential to the success of such tissue engineering approaches. In our 
laboratories we use dental pulp/stromal cells (DPCs) as a source of precursor cells which 
can be differentiated to an osteogenic phenotype by culture under appropriate conditions. In 
order to address some of the issues raised above we have examined the expression and 
activity of the IGF axis in DPCs which have been induced to differentiate to an 
osteogenic/matrix mineralising phenotype in vitro. We found that DPCs express all 
components of the IGF axis (except IGF-I and IGFBP-1) under both basal and osteogenic 
conditions. With respect to IGFBPs we report that IGFBP protein concentrations in DPC 
conditioned medium closely follow mRNA levels prepared from DPCs. IGFBP-4 is the most 
abundant IGFBP in both basal and osteogenic DPCs and levels are not altered between 
basal and osteogenic cultures. IGFBP-4 and -5 inhibit IG-I and IGF-II stimulated osteogenic 
differentiation in DPCs. Of some interest although IGFBP-4 expression is not altered by 
differentiation of DPCs IGFBP-4 proteolysis is enhanced under osteogenic conditions. 
Subsequently we found that pregnancy associated plasma protein-A (PAPP-A) is the sole 
IGFBP-4 protease in DPC conditioned medium and its concentration is increased under 
osteogenic conditions. Further IGF-II (an activator of PAPP-A) and stanniocalcin-2 (STC2- 
10 
 
an inhibitor of PAPP-A) concentrations are respectively increased and decreased during 
osteogenic differentiation of DPCs. We suggest that our data may represent a series of co-
ordinated changes in IGF axis expression and activity which represent a novel osteogenic 
“signature” of differentiating DPCs. 
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Chapter 1 Introduction 
1.1 General Introduction 
The current study is concerned with some aspects of the biology of cells derived from dental 
pulp tissue (dental pulp cells – DPCs). In particular we will discuss a series of studies which 
examines the differentiation of DPCs into cells displaying characteristics of an osteogenic 
phenotype with the ability to secrete a mineralising matrix. Our focus will be to extend our 
previous studies on the role of the insulin-like growth factor (IGF) axis on the regulation of 
this process [1-3] and to describe how novel co-ordinated transcriptional and post-
transcriptional changes in the expression and activity of the genes associated with the IGF 
axis affect the osteogenic differentiation of DPCs. We propose that such changes represent 
an “osteogenic signature” characteristic of differentiating DPCs and discuss how further 
understanding of such local growth factor signalling cues may assist in the development 
strategies for the use of DPCs in hard tissue engineering programmes. We begin our 
literature review with a discussion of some relevant aspects of dental pulp and DPC biology. 
1.2 Dental Pulp Biology 
1.2.1 Development of dental pulp tissue 
 
Dental pulp tissue is derived from cells of both ectodermal (neural crest) and mesodermal 
(mesenchymal) origin [4] During the “bell” stage of tooth development (Fig 1) neural crest 
derived cells develop into an odontoblast (O) layer towards the periphery of a condensed 
mesenchymal dental papilla tissue (P) which will form the remainder of the mature dental 
pulp tissue. Under the influence of humoral factors secreted by the outer enamel epithelium 
(OEE) the closely opposed odontoblast layer secretes pre-dentin (PD) which in due course 
will develop into mature tertiary dentin. Pre-ameloblasts (A) derived from the OEE at this 
stage secrete an early form amelogenin matrix which is juxt-opposed to the pre-dentin layer. 
The outer and inner enamel epithelial layers meet at the cervical loop (CL) and downward 
growth of this structure as Hertwig’s sheath represents the precursor of the root structure. 
19 
 
Anatomical relationships amongst the various cell types at this stage of tooth development 
are represented in Fig 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   oee - outer enamel epithelium; a – ameloblast layer; o – odontoblast layer; pd –   
   predentin; p-pulp; cl – cervical loop See text for further details. Adapted from  
   https://pocketdentistry.com/wp-content/uploads/285/c03f00412.jpg. 
 
 
 
 
 
 
 
 
 
 
Figure 1 Cell types and anatomical relationships during the bell stage 
of tooth development 
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1.2.2 Dental pulp stem cells (DPSCs) 
 
The presence of stem cell populations within the dental pulp was first described at the 
beginning of this century when transplantation of DPSCs into immunocompromised mice 
along with hydroxyapatite/tricalcium phosphate (HA/TCP) carrier led to the formation of 
dentin like structure in vivo  [5]. Encouragingly these structures recapitulated some of the 
structural details of dentinal pulp present in situ including a peripheral odontoblast-like layer 
surrounding a rudimentary dental pulp. Following these initial observations DPC populations 
were further characterised by our group and others in respect of the expression of typical 
stem cell surface markers [2, 6, 7]. This characterisation was typically obtained through 
fluorescence activated cell sorting (FACS) analysis with +ve selection for markers such as  
CD29, CD90, CD105, CD146, CD166 and CD271 and –ve selection of haematopoietic stem 
cell specific markers CD34 and CD45. On occasion expression of pluripotent stem cell 
markers such as NANOG and OCT4 in DPC populations has also been confirmed by 
techniques such as qRT-PCR [8, 9]. Although the proportion of putative stem cells in 
heterogeneous populations of DPCs has varied widely amongst different studies [10-12] 
DPSCs are perceived to have advantages over stem cells derived from other tissue 
compartments. For example, they can be easily isolated from the pulp of extracted teeth 
(typically discarded in the clinic) grown then expanded and stored for future use. On isolation 
DPCs demonstrate a fibroblast-like morphology and proliferate quickly during culture and 
following passage (Fig 2) although as a caveat there are very few studies which have 
systematically examined retention of pluripotency during serial passage of cells. However, in 
combination with tooth banking programme such an approach provides a source of cells for 
autologous regenerative strategies. In addition to adult dental pulp stem cells have been 
isolated from other dental tissues including periodontal tissue (PDLSCs) [13], apical papilla 
(SCAP) [14], dental follicle (DFSCs) [15],  pulp tissue isolated from and deciduous teeth 
(SHED) [16] see Fig 3. As all of these tissues share a mixed ectoderm/mesoderm embryonic 
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origin, they share many of the properties of pluripotent embryonic stem cells and can 
differentiate into several different phenotypes under appropriate culture conditions [17, 18].  
  
  
(left) Appearance of dissected dental pulp tissue.  
Adapted from https://www.capstonedental.com.au/blog/ask-the-dentist-sensitive-teeth 
(upper right) appearance of fibroblast-like undifferentiated DPCs. 
 Adapted from https://imgur.com/gallery/Q2Qrq/comment/546728917 
(lower right) isolated following tissue digestion. 
 
 
 
Figure 2 Anatomical relationship of dental pulp with other structures in adult 
tooth 
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DPSCs- dental pulp stem cells; PDLSCs - periodontal ligament derived stem cells; SHED - 
stem cells from exfoliated dental pulp; SCAP- stem cells from apical papillae; DFSCs - 
dental follicle stem cells; TGPCs - tooth germ progenitor derived stem cells.  
(Adapted from: http://www.slideshare.net/hamedgholami104/dental-stem-cells-18007596) 
 
 
 
 
 
 
Figure 3 Location of stem cell niches in the oral cavity 
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1.2.3 Differentiation of DPSCs 
 
The embryonic origin of dental tissues is from both oral ectoderm and neural crest derived 
mesenchyme and because of this these tissues (including dental pulp) contain populations 
of stem cells with a pluripotent potential similar to that that displayed by embryonic stem 
cells. Accordingly under appropriate culture conditions they can differentiate into many 
different phenotypes [17, 18] see Fig 4. Similarly we and others have identified the cell 
surface expression of stem cell markers of the surface of DPCs [19-21].This work also 
characterised these cell populations as adherent to plastic with a high proliferative potential 
and an ability to self-renew which is characteristic of typical stem cell populations. Although 
the literature contains studies describing the differentiation of DPCs down adipogenic [22-
24], angiogenic [25, 26],neurogenic [15, 27] and myogenic [28] lineages by far the majority of 
studies have examined the differentiation of DPCs to odontogenic or osteogenic phenotypes   
[29-31]. This reflects the fact that the formation of dentin (odontogenesis) or bone 
(osteogenesis) from DPCs may be a route for in situ repair of various dental tissue injuries or 
even provide the means for reconstruction of hard tissues from other anatomical locations. 
Accordingly several in vitro studies have shown that DPCs can functionally differentiate into 
osteoblasts and secrete a mineralizing matrix [32, 33], Further when such cells are 
transplanted into immunocompromised mice they form bone like structures in vivo [34, 35]. 
The formation of appropriate dentin structure in vivo is only described in a few studies [36, 
37] and for both dentin and bone formation from transplanted DPCs  spectrophotometric or 
microscopic confirmation of appropriate 3D tissue structure has not been universally 
confirmed. Nonetheless for dentin physiological differentiation occurs following trauma/injury 
where DPCs differentiate into odontoblast-like cells which secrete reparative dentin in an 
attempt to minimize tissue degradation. 
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Right photo is adapted from 
https://rickwilsondmd.typepad.com/rick_wilson_dmds_blog/2010/09/dental-pulp-calcification-
spelunking-in-the-dentin.html  see [7, 38-42]. 
 
chondrogenic 
adipogenic 
neurogenic 
angiogenic 
myogenic 
Figure 4 Dental pulp stem cells can be differentiated down numerous phenotypic 
lineages 
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1.3 Growth factor regulation of osteogenesis 
In our laboratory and in other groups the osteogenic differentiation of MSCs (including 
DPCs) is achieved by the addition of glucocorticoid (typically dexamethasone) and ascorbic 
acid (vitamin C) [2, 43, 44]. In some occasions the nucleation factor β-glycerophosphate is 
also used although this may lead to non-physiological deposition of mineral in cell cultures 
[45]. However, in vivo the differentiation of DPCs into a matrix mineralising phenotype most 
likely occurs through more physiologically relevant routes. This is typically associated with 
expression of osteogenic markers including alkaline phosphatase (ALP), osteocalcin (OCN) 
and runt-related transcription factor 2 (Runx2) along with an extracellular protein matrix 
which is characteristic of mineralised tissues and leads ultimately to the deposition of 
inorganic calcium-phosphate (Ca-P) within this matrix. It is important in these circumstances 
that appropriate 3D structure of hard tissue is achieved and although some successful 
studies using xenograft transplantation in immunocompromised mice have been reported 
[10] the appropriate 3D structure of this tissue is often not rigorously confirmed. One reason 
for this may be the absence of appropriate physiological signals in the form of growth factor 
or other cytokine gene expression and signalling in situ. Further research is needed in this 
area and initially work has been reported on the bone morphogenetic protein (BMP) family. 
These proteins belong to the Transforming growth factor-Beta (TGF-β) superfamily and are 
extensively reported to  play an important roles in the development and maintenance of 
skeletal tissues including tooth development -see [46] for recent review. Therefore various 
lines of evidence have shown that individual BMPs will stimulate the  differentiation of 
mesenchymal stem cells (MSCs) into osteoblast progenitor cells [47-49] However in human 
bone tissue matrix by far the most abundant growth factor is insulin-like growth factor-1 (IGF-
I) and this polypeptide growth factor acts in concert with pituitary growth hormone to regulate 
long bone accretion in childhood [50].As our experimental work examines the involvement of 
the IGF axis in osteogenic differentiation at this stage we provide a short review of the 
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literature which describes the role of IGFs in skeletal maintenance and development. This is 
followed by a more detailed analysis of the components of the IGF axis 
 
1.3.1 IGF axis and bone physiology 
 
Genetically engineered mice provided some of the first evidence for the importance of the 
IGF axis in the development and maintenance of skeletal tissues. IGF-I heterozygous or 
homozygous null mice showed reduced post-natal growth although homozygous null mice 
showed a large degree of perinatal death [51, 52]. In terms of bone structure authors have 
described a “mixed phenotype” in IGF-I null mice with a reduction in cortical but increased 
trabecular bone density and connectivity. It has been suggested that this may be due to the 
fact that IGF1 has effects on both osteoblast and osteoclast cell biology. Studies with igf1-r 
knock out mice have proved more problematic as these animals invariably die perinatally 
[52]. However, cre-lox specific deletion of the igf-1r in osteoblasts resulted in several 
alteration of bone trabecular structure including reduced trabecular number and volume [53]. 
In contrast to the above studies over expression of IGF1 from a metallothionein promoter 
resulted in increased body weight gain but very little discernible phenotype in skeletal 
structure. In an attempt to dissect out the contribution of local versus systemic circulating 
IGF to body growth several sophisticated tissue specific KO transgenic animals have been 
generated [54-58]. In summary these studies have shown that endocrine IGF-I derived from 
the liver is not required for normal body growth but this endocrine source of IGF-I can 
compensate for a lack of locally produced IGF-I in skeletal tissue. It is therefore highly likely 
that both circulating and locally produced IGF-I are required for normal development and 
maintenance of skeletal tissues. 
Many lines of evidence confirm the importance of the IGF axis in development and 
maintenance of skeletal tissues in humans.  In cases of pituitary growth hormone (GH) 
deficiency-where IGF-I levels are also decreased, reduced bone mineral density is apparent 
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and this can be countered by GH administration leading to increased serum IGF-I [56, 59, 
60]. Similarly mutations of the GH receptor as seen in Laron syndrome [61] lead to low 
serum IGF-I levels and severe growth restriction in affected individuals. In addition mutations 
in the IGF-I gene leading to lowered plasma levels of the growth factor [62-64] or mutations 
in the IGF-I gene itself [65-67] are associated with intrauterine and postnatal growth defects. 
This area has been the subject of an excellent recent review [68]. 
 In mature adult bone IGF-I and IGF-II regulate the differentiation and activity of osteoblasts 
and osteoclasts and as such are critically important in the process of bone remodelling [53]. 
The activity of IGFs in bone physiology is regulated by six soluble high affinity IGF binding 
proteins (IGFBP 1-6). IGFBPs have the ability to enhance or inhibit the action of IGFs in a 
tissue specific manner (including bone) and also display IGF independent effects [69]. 
However, importantly in the context of tissue engineering, IGFBPs are present at a high 
concentration within bone matrix where they are believed to form tripartite complexes with 
IGFs and extracellular matrix molecules (collagen, fibronectin, laminin). As such they may 
form a low affinity sink for IGFs within bone tissue from which growth factor can be released 
into the pericellular environment to act through cell surface IGF-I and IGF-II receptors 
(IGF1R and IGF2R) [70, 71]. This naturally occurring regulation of bone metabolism may 
provide a route for more realistic approaches to hard tissue engineering where delivery of 
active growth factor is achieved through normal cell physiology. It is clear from the above 
that the IGF axis is multicomponent and as the main experimental section of this thesis deals 
with the potential role of the IGF axis in the osteogenic differentiation of DPCs it is 
appropriate that we provide some more detail with respect to the IGF axis genes and 
proteins and discuss further their role in hard tissue metabolism including tissues in the oral 
cavity. This area has been reviewed recently by our group and others [70, 71] 
1.4 IGF axis – molecular components 
The IGF axis comprises two polypeptide growth factors (IGF-I and IGF-II), two cell surface 
receptors (IGF1R and IGF2R) and six soluble high affinity IGF binding proteins (IGFBP-1-6) 
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[72, 73]. In addition to this a number of ancillary proteins also interact with the main IGF axis 
gene products – see below. A diagrammatic representation of the main IGF axis proteins is 
provided in Fig 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The IGF axis comprises 2 growth factors (IGF-I and IGF-II); cell surface cognate IGF 
receptors IGF1R and IGF2R and 6 soluble high affinity IGF binding proteins (IGFBP1-6). An 
acid labile subunit (ALS) is able to bind to IGF: IGFBP-3/5 binary complexes to form a 
tripartite complex. IGF-I and IGFII both bind to the IGF1R although affinity of IGF-I for IGF1R 
is 10-fold higher than IGF-II. IGF-II also binds to the insulin receptor isoform a (IR-A) and 
both growth factors also bind to hybrid receptors formed between IGF1R and IR-A. Note 
IGF-II = IGF2. Adapted from Yau et al [74].  
Figure 5 Components of the IGF axis 
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1.4.1 IGFs 
 
IGF-I is a 70 amino acid polypeptide (7.5 KDa) hormone encoded on chromosome 12 
(human) with structural homology to insulin. In biological fluids a large majority of IGF-I is 
bound to the high affinity IGFBPs such that only around 1% of total IGF-I is present in the 
free form. Total concentration (free and bound) in plasma is of the order of 150-400ng/ml. 
Liver is the main source of IGF-I and in this tissue expression is positively regulated by 
pituitary growth hormone (GH). However, IGF-I is expressed by several other tissues - 
including skeletal tissues (muscle, bone, and cartilage) and transgenic mice with tissue 
specific knock out of hepatic IGF-I display a normal growth phenotype indicating the 
importance of peripheral and local synthesis of the growth factor in whole animal physiology. 
IGF-I has pleiotropic actions regulating cell development, proliferation, differentiation and 
migration as well as exhibiting anti-apoptotic actions [75, 76]. and many of these activities 
occur through autocrine and paracrine mechanisms [77]. IGF-II is of a similar size to IGF-I 
(67 residues) but is a distinct gene product encoded on human chromosome 11. IGF-II 
concentrations peak during foetal growth and then decline in adult life. IGF-II expression is 
not GH dependent [78] 
 
1.4.2 IGF receptors 
 
IGF-I activity is mediated at the cell surface by IGF1R which is a heterotetrameric 
transmembrane tyrosine kinase receptor [79]. It comprises two extracellular α-subunits 
containing the IGF binding domain and these are connected by disulphide bonds to two 
transmembrane β-subunits that contain tyrosine kinase activity [80-82]. When IGF-I binds to 
the α subunits, the β subunits undergo conformational changes which stimulates tyrosine 
kinase activity causing activation of downstream signalling molecules by further protein 
phosphorylation [77]. Among these are the SRC homology 2 domain-containing protein 
(SHC) and insulin receptor substrate family of proteins (IRS1-4). These signalling 
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intermediates play an important role in activation of the phosphoinositide 3 kinase (PI3K) 
and mitogen-1 activated protein (MAPK) kinase pathways [82]. The biological effects of IGF-
II are also believed to be transduced through the IGF1R although IGF-II binds to IGF1R with 
a lower affinity than IGF-I. The cognate receptor for IGF-II (IGF-2R) is a mannose- 6- 
phosphate receptor and binds both IGF-I and IGF-II although with a higher affinity for IGF-II 
compared with IGF-I [83]. Although no biological action as yet been definitively assigned to 
the  IGF-2R it  is a key player in IGF-II turnover and degradation [84]. In addition by diverting 
IGF-II from binding to the IGF1R it has been suggested that IGF2R may act as a tumour 
suppressor [85] although further evidence is required to substantiate this suggestion. 
There is a high degree of similarity between insulin receptor (IR) and the type I IGF receptor 
(IGF-IR). IR activation involves stimulation of intracellular mediators that results in the 
regulation of cell metabolism, proliferation and survival. Generally, IR has anabolic effects, 
while IGF-IR has antiapoptotic, mitogenic, and transforming effects. The IR can be 
stimulated by IGF-II, IGF-II sends a proliferative signal through the IR. Insulin receptor has 
two isoforms: isoform A (IR-A) and isoform B (IR-B). IGF-II binds with higher affinity to IR-A 
than IR-B. IR-A, produced by exon 11 skipping, is characterized by the absence of 12 amino 
acid residues at the carboxyl terminus of the IR α -subunit and is predominantly expressed in 
fetal tissues and cancer cells. On the other hand, IR-B, containing the 12 amino acid 
residues encoded by exon 11, binds insulin well and IGF-II poorly, and is usually expressed 
in adult differentiated cells [86]. 
 
1.4.3 IGF binding proteins (IGFBPs) 
 
The 6 IGFBPs are secreted in a cell and tissue specific manner and are soluble high affinity 
IGF binding proteins[77].IGFBPs are 24-42 kDa proteins and share a generic structure 
comprising highly conserved N- and C-terminal domains connected by less well conserved 
flexible linker domain. The N- and C-terminal domains are characterised by a highly 
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conserved intra-domain disulphide bonding pattern and both domains contribute to IGF 
binding. Most IGFBPs contain heparin binding sites within the C-terminal domain and in 
some instances a cryptic heparin binding site in the central domain [87]. IGFBP-1 and -2 
also have RGD integrin binding motifs in the C-terminus. Figure 7 shows a highly stylised 
representation of the generic IGFBP domain relationships. To date there has been no report 
of a 3-dimensional structure for an entire IGFBP protein. This is most likely due to the highly 
flexible nature of the central IGFBP linker region which bridges the N- and C-terminal 
domains of the protein which makes crystallisation of proteins difficult. However partial 
solved structures for isolated domains reveal a largely β-barrel like structure and homology 
modelling as ben used to infer this conserved 3D structure amongst all the IGFBPs. Figure 8 
shows a representation of solved N- and C-terminal domain structures for IGFBP-4 in 
complex with bound IGF-I IGFBP domain and tertiary structure.  IGFBPs are subject to post-
translation modifications (PTM). Therefore IGFBP-3 is extensively glycosylated and IGFBP-1 
is subject to serine phosphorylation which reduces its affinity for binding IGFs. However, in 
the context of our report the most important PTM of IGFBPs is that of proteolysis. We will 
discuss this extensively for IGFBP-4 and IGFBP-5. Because of the fact that IGFBPs have a 
10-fold higher affinity for IGFs comprising than the cell surface IGFRs, this has important 
physiological consequences and is relevant to the Experimental section of this thesis. In 
biological fluids 99% of circulating IGFs are bound to IGFBPs [88] and this may represent a 
reservoir depot of IGFs [77, 89]. In addition association of IGFs with IGFBPs may represent 
a buffering of IGF activity in that IGFs are present at around x1000-fold higher concentration 
than insulin and the presence of large concentrations of free IGFs in the circulation may 
induce hypoglycaemic shock [90]. IGFBPs affinity for IGFs can be affected by post-
translational modifications of these proteins and particularly by proteolysis [89, 91]. As this is 
also an important part of the Experimental section of this thesis we discuss this topic at 
greater length below. Finally, IGFBP-3 and -5 are commonly found in a ternary complex with 
an acid labile subunit (ALS) which has the effect of inhibiting trans endothelial passage of 
IGF: IGFBP complexes [92, 93]. A short description the function of each of the IGFBPs 
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follows with special emphasis on IGFBP-4 – the main IGFBP species investigated in this 
work. 
 
 
 
Also shown are the heparin binding domains in the C-terminal domain (HBD-2) and a cryptic 
heparin binding domain (HBD-1) in the central domain. Integrin binding domains (RGD) are 
also present in the C-terminal domains of some IGFBPs. Finally, IGFBPs are subject to 
proteolysis by several families of protease enzymes. As indicated these sites are located 
mainly in the central domain. Figure is adapted from Russo et al [94]. 
 
 
 
 
 
 
Figure 6 The generic 3 domain structure of IGFBPs shows IGF binding elements in the 
N- and C-terminal domains 
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(blue) interaction with the solved structures for the N-terminal (yellow) and C-terminal (grey) 
domains of IGFBP-4 Residues in IGF-I which are involved in binding the N- and C-terminal 
domains are highlighted. Note as indicated that affinity of IGF-I for IGFBP is over 10-fold 
higher than for cell surface IGF1R (see text for further details). Figure adapted from 
Siwanowicz et al [95].  
 
 
Affinity ~ 0.2 nM 
Cf. IGF1R ~ 2nM 
Figure 7 Space filling 3D model of IGF-I 
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IGFBP-1 
 
 IGFBP-1 stimulates cell motility, adhesion and migration. It binds specifically to the α₅β₁ 
integrins [89, 96], and is present at very high concentrations in placenta. There are higher 
IGFBP-1 concentrations in female plasma compared to male plasma [97]. IGFBP-1 
expression is inversely regulated by insulin and phosphorylation of IGFBP-1 reduces IGF 
affinity [89]. . IGFBP-1 is expressed at low levels in primary hOB cultures under  regulation 
of glucocorticoid and insulin  although the physiological relevance of this effect in bone 
tissue has not been established [98]. A recent prospective study (10 year follow up) in a 
cohort of elderly women reported a positive correlation between serum IGFBP-1 and 
osteoporotic fracture, suggesting an IGF-independent osteopenic effect of IGFBP-1[99]. 
Further data are required on IGFBP-1 and its effects (if any) on bone physiology.  
 
IGFBP2 
 
There is a literature describing IGF-dependent and IGF-independent effects of IGFBP-2 in 
osteoblast cultures and bone tissues. An early study using a unilateral disuse osteoporosis 
model in the rat showed that osmotic minipump delivery of IGF-II/IGFBP2 complexes 
prevented the decrease in BMD in affected femurs associated with this model [100]. A 
subsequent report from the same group showed that IGF-II/IGFBP2 complexes bound to 
heparin-sepharose and it was suggested that such complexes may associate with ECM 
components in bone tissue potentially increasing the local concentration of IGFs [101]. In 
agreement with the above findings, IGFBP-2 potentiated IGF-II-induced increases in ALP 
activity in cultures of rat tibial osteoblasts [102], and we have demonstrated the same effect 
of IGFBP-2 on IGF-I stimulated ALP activity in differentiating DPCs [1]. Studies in IGFBP-2 
KO mice indicated gender specific differences in osteogenic phenotype with increased 
cortical thickness and periosteal circumference in female mice but reduced cortical bone 
area and trabecular volume in male KOs [103]. Although difficult to rationalise, it clearly 
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suggests interplay between the IGF axis and other hormone systems. This same group also 
reported impaired osteoclastogenesis in bone marrow cells derived from igfbp2 -/- mice and 
a transfection  study in these cells indicated that both the IGF and heparin binding domain of 
IGFBP-2 was required for osteoclast generation [104] This description of IGF-independent 
effects of IGFBP-2 in vitro was confirmed in concurrent studies demonstrating restoration of 
osteogenic phenotype in igfbp2 -/- bone marrow cells by addition of a heparin binding 
domain (HBD) peptide derived from IGFBP2. In addition, in vivo administration of HBD 
peptide restored osteoblast number in igfbp2 -/- mice [105]. Recently studies in the mouse 
MC-3T3 pre-osteoblast cell line showed that IGFBP-2 can bind and inhibit the activity of 
receptor phosphotyrosine phosphatase β (RPTP β) causing increased levels of 
phosphorylated PTEN, activation of Akt and stimulation of osteogenesis [105, 106]. Further 
reports from this laboratory highlight the importance of the scaffold/adaptor protein IRS-1, 
PKCζ and early activation of AMP dependent protein kinase (AMPK) in the osteoblast 
differentiation of primary rat calvarial cells and the differentiating MC-3T3 cell line [107, 108]. 
It should be noted that IGFBP-2 is also a Pregnancy Associated Plasma Protein -A (PAPP-
A) substrate, although this IGFBP is cleaved less efficiently than IGFBP4 and IGFBP-5 
[109]. 
 
IGFBP-3 
 
IGFBP-3 is the most abundant IGFBP in serum and reaches highest levels during puberty. 
IGFBP-3 provides 75-80% of the IGF carrying capacity in serum and binds IGFs in high 
affinity complexes. The IGF-I-IGFBP3 complex forms a tripartite complex with a third protein 
known as acid labile subunit (ALS) – see page 28 and this prolongs the circulating half-life 
(~16 hours) of bound IGF-I compared to free growth factor (<15 minutes) [77] . Around 90% 
of IGFBP-3 and 55% of IGFBP-5 circulate in a trimeric complex with ALS during adult life 
[110]. Interestingly and pertinent to the current study, IGF action on osteoblasts is enhanced 
by IGFBP-3 [111]. A very early study reported inhibition of IGF-I stimulated DNA synthesis in 
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two osteoblast cell lines by intact IGFBP-3 [112]. This inhibitory effect on both IGF-I and IGF-
II stimulated DNA synthesis was confirmed in cultures of rat calvarial cells [113]. Although 
this data suggest an inhibitory role for IGFBP-3 in bone metabolism, other in vivo data [114] 
and cross-sectional studies in a cohort of female patients with postmenopausal osteoporosis 
suggest an anabolic role for IGFBP-3 in maintaining bone density [115].  
 
IGFBP-5 
 
IGFBP-5 is also present at high concentrations in bone matrix and has been associated with 
both inhibitory and stimulatory activities in bone cells and tissues. IGFBP-5 was reported to 
have IGF-dependent and IGF-independent effects in bone tissue although the literature is 
conflicted in this area. IGFBP-5 was shown to enhance IGF-stimulated mitogenesis in hOB 
cultures [116, 117]  and to stimulate the differentiation of two osteoblast cell lines in an IGF-
independent fashion [118, 119].  In ovariectomised  rats, daily subcutaneous injection of 
IGFBP-5 increased osteoblast proliferation [120] and enhanced the  association of IGF1 with 
bone cells possibly via specific cell-surface binding sites for IGFBP-5 [121, 122] or through a 
specific IGFBP-5 receptor on osteoblast membranes [123, 124]. Disappointingly however a 
specific IGFBP-5 receptor has not been isolated or characterised further. Signalling studies 
suggest that the actions of IGFBP-5 in osteoblasts involve Ras association family isoform C 
(RASSF1C) activation of Erk-1/2 [125]. The association of IGFBP-5 with four and a half lim 
domain protein (FHL2) within the nucleus of U2 osteosarcoma cells has also been reported 
although the functional significance of this observation remains unknown [126]. Although all 
the above findings are consistent with a stimulatory role for IGFBP-5 action in bone tissue 
(IGF-dependant or independent), some authors have reported contrary findings.  For 
example, IGFBP-5 was reported to inhibit IGF-I stimulated proliferation in the U2 human 
osteosarcoma cell line [127] and transgenic mice expressing IGFBP-5 from the osteocalcin 
promoter showed decreased trabecular bone formation and reduced rates of mineral 
deposition during the first few weeks of post -natal life [128]. Stromal cells isolated from 
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transgenic animals also showed decreased levels of osteogenic markers. Constitutive over 
expression of IGFBP-5 in the mouse osteoblast precursor cell line MC3T3-E1 also 
decreased osteogenic marker expression and delayed formation of mineralised nodules 
under osteogenic culture conditions [129]. Finally, addition of exogenous wtIGFBP-5 or 
expression of IGFBP-5 from an adenovirus promoter inhibited osteoblast differentiation and 
growth of mouse metatarsal bones in short term culture [130].  
Although IGFBP-5 is cleaved in an IGF-independent fashion by PAPP-A and PAPP-A2, it is 
also a substrate for other proteolytic enzymes. Matrix metalloproteinase -1 and -2 (MMP-1 
and MMP-2)  were shown to degrade IGFBP-5 in a time-dependent fashion in medium 
conditioned by the mouse MC-3T3-E1 cell line [131], and the complement component C1s 
was identified as an IGFBP5 specific protease in human dermal fibroblast conditioned media 
[132]. Following on from this, Mohan et al described ADAM-9 (a disintegrin and 
metalloprotease -9) as an IGFBP-5 protease expressed the U2 human osteosarcoma cell 
line [133]. Although the importance of IGFBP-5 proteolysis may (as for IGFBP4 proteolysis) 
lie with the regulation of free pericellular IGF concentrations, this is somewhat complicated 
by the observations of IGF-independent actions of IGFBP-5 described above. Clearly, these 
may also be impacted by IGFBP-5 proteolysis. Further work is required to establish the role 
of IGFBP-5 in osteoblast differentiation and in bone tissue metabolism in general.  Finally, 
there are reports of broad-spectrum proteolytic enzyme families which degrade IGFBP-5 
(and other IGFBPs). Among these are the serum proteases plasmin [134] and 
thrombin[135], and other tissue serine proteases including cathepsin G and elastase [136]. 
However, issues in regard to the specificity and physiological role of these proteases remain 
to be answered.  
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IGFBP-6 
 
IGFBP-6 mRNA was expressed in primary osteoblast cultures derived from foetal rat 
calvaria [137] and both mRNA and protein expression was up regulated in a dose-dependent 
fashion by cortisol or retinoic acid treatment [138, 139] cultures. Conversely IGFBP-6 
expression was negatively regulated by TGFβ1 in the same cell culture system [140]. 
IGFBP-6, uniquely amongst the IGFBP family shows a higher affinity for IGF-II than IGF-I. 
Accordingly, it was shown to be a more potent inhibitor of IGF-II stimulated DNA and 
glycogen synthesis in hOB cells than IGF-I [141]. This inhibitory effect of IGFBP-6 was 
confirmed in the SaoS2 human osteosarcoma cell line using a stable antisense transfection 
strategy to demonstrate that the anti-differentiative activity of all-trans retinoic acid (at-RA – 
Vitamin D) was at least partly mediated via IGFBP-6 [142].More recently IGFBP-6 has been 
shown to interact with the thyroid hormone receptor alpha1 (TR alpha1) and to inhibit the tri-
iodothyronine (T3) induced increase in osteoblast marker expression in the human U2-OS 
osteosarcoma cell line [143]. In contrast to these reports the inhibitory effect of IGFBP-6 
attenuated by intracellular interaction with the LIM mineralising protein (LIMP) in both human 
and mouse osteoblastic cells [144] and one study reported a stimulatory effect of IGFBP-6 
on DNA synthesis and mitogenesis in the human osteosarcoma Saos-2/B-10 cell line [145]. 
As for IGFBP-1 and IGFBP-3, the role of IGFBP-6 in osteogenesis and bone tissue 
physiology has been underreported and further studies are required to elucidate the role of 
these 3 IGFBPs in osteogenesis and bone physiology. 
 
1.4.4 IGFBP-4  
 
IGFBP-4 was first identified as an inhibitory IGFBP in medium conditioned by the TE89 
human osteosarcoma cell  line [146] and then cloned from cDNA  libraries of various tissues 
in human and rat [147, 148]. It is a 237-residue protein sharing the 3-domain structure 
previously described for other IGFBPs – see Fig 8 for details of IGFBP-4 primary structure. 
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Early studies showed that IGFBP-4 inhibited IGF-II stimulated thymidine uptake in primary 
cultures of human osteoblasts [121] and in the MC3T3-E1mouse osteoblast cell line [149] 
and  inhibited IGF-I stimulated amino-isobutyrate uptake in bovine fibroblasts and in  the rat 
neuronal B104 cell line [150, 151]. This inhibitory activity in vitro led to the hypothesis that 
IGFBP-4 generally displayed anti-anabolic and anti-proliferative effects. In confirmation of 
this, overexpression of IGFBP-4 in a malignant prostate epithelial cell line decreased the 
proliferative response to IGF-I and delayed tumour development when transfected cells were 
transplanted into nude mice [152].  In vivo data also supported an inhibitory role for IGFBP-
4. Tissue specific overexpression of IGFBP-4 in smooth muscle cells using an α-actin 
promoter caused smooth muscle hypoplasia [153] and a  similar strategy using a protease 
resistant form of IGFBP-4 (see 1.4.5 IGFBP4 proteolysis ) resulted in transgenic mice with 
decreased  internal smooth muscle mass in stomach, bladder and aorta [154]. Importantly 
with respect to this review, IGFBP-4 over expression in osteoblasts decreased bone 
formation and compromised global skeletal growth [155]. Some epidemiological data also 
supported an inhibitory role for IGFBP4 with increased levels in a cohort of female patients 
with age-related osteoporotic fractures of the hip and spine [156]. Although this evidence 
suggested an inhibitory role for IGFBP4, other reports indicated an anabolic role for IGFBP4. 
Therefore, systemic administration of IGFBP-4 to mice increased bone tissue markers 
(osteocalcin and alkaline phosphatase) in serum and skeletal tissue [157]. Additionally, 
IGFBP-4 knock out (KO) mice exhibited prenatal growth retardation, suggesting that IGFBP-
4 may be required for full growth promoting effects of IGF-II in the foetus [158]. IGFBP-4 KO 
mice also showed gender dependent changes in skeletal phenotype with female mice having 
reduced BMD along with other features associated with osteopenia [159]. Clearly further 
research is required to definitively establish the role of IGFBP-4 in bone tissue physiology. In 
this respect, the observation of IGFBP4 proteolysis by fibroblast and bone cell cultures have 
attracted much interest as a means of regulating the activity of IGFs in bone and other 
tissues and we provide a short summary of this area in the following section. 
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The 21 residue signal peptide sequence is displayed in grey above the N-terminus of the 
mature protein. Residues comprising the N-terminal (yellow), C-terminal (green) and central 
(black) domains are highlighted. The location of 6 N-terminal and 3 C-terminal intra-domain 
disulphide bridges are indicated. These are conserved in all IGFBP species. A disulphide 
bridge unique to IGFBP-4 is also present in the central domain. The location of the N-linked 
glycosylation site at N104 is indicated in blue and the PAPP-A cleavage site between M135 
and K136 is indicated by an arrow. Adapted from [160]. For further details see 
http://www.uniprot.org/uniprot/P22692 
 
 
 
 
 
 
Figure 8 The primary sequence of IGFBP-4 
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1.4.5 IGFBP-4 proteolysis 
 
Addition of IGF-I to cultures of human fibroblasts reduced the levels of a 24 kDa IGFBP in 
conditioned medium and development of specific antibodies confirmed this species as 
IGFBP4 [161, 162]. IGF-I dependent down regulation of IGFBP4 occurred independently of 
IGF1R activation and was not associated with changes in IGFBP4 mRNA levels suggesting 
a direct post-translational regulation of IGFBP4 by IGF-I. Shortly thereafter, IGF-induced 
decreases in IGFBP-4 protein were shown to be due to the presence of a proteolytic activity 
in fibroblast conditioned medium which in cell free assays was activated by IGF-I or IGF-II 
[163]. IGFBP-4 was cleaved into two discrete fragments by this protease, suggesting a 
specific cleavage point within the protein [164]. The cleavage site was identified at the 
peptide bond M135-K136 within the central domain of IGFBP4 producing 14 and 18kDa 
protein fragments [151]. This data was used to engineer protease resistant IGFBP4 mutants 
which have proven useful in the further study of the biological significance of IGFBP4 
proteolysis [151, 165] and became apparent when intact, but not cleaved IGFBP-4, was 
shown to inhibit [3H] aminoisobutyric acid uptake into bovine fibroblasts with the inference 
that cleaved IGFBP-4 fragments did not bind IGF-I. Further study indicated that IGF-II was a 
more potent activator of IGFBP-4 proteolysis than IGF-I and IGF-II pre-treatment of human 
dermal fibroblast cultures increased sensitivity of cell cultures to IGF-I.  The concept of IGF-
II-mediated IGFBP4 proteolysis as a route for increasing sensitivity to IGF-I [166] may be 
significant as IGF-I and IGF-II are usually present together in the pericellular environment  
suggesting a complex interaction between the growth factors to regulate anabolic responses.  
Primary cultures of human osteoblasts (hOB)  expressed IGFBP-4 protease activity identical 
to that described for fibroblasts [167], and pre-treatment of osteoblast cultures with IGF-II 
also increased sensitivity to IGF-I stimulated [3H] thymidine incorporation [168]. 
Subsequently, IGFBP-4 protease activity has been reported in human endometrial stromal 
cells [169] and in porcine aorta derived smooth muscle cells [170], suggesting that 
proteolysis of IGFBP-4 may have widespread biological significance. At around this time a 
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landmark study identified pregnancy-associated plasma protein-A (PAPP-A) as the enzyme 
responsible for IGF-dependent cleavage of IGFBP-4 in fibroblast conditioned medium [171] . 
PAPP-A was also shown to proteolyse IGFBP-5 although in this instance proteolysis 
occurred independently of IGF [172] . Identification of PAPP-A as the IGF-dependent 
IGFBP-4 protease expressed caused a paradigm shift in this area of IGF research.  
Whereas previously IGFBP-4 had been viewed mainly as an inhibitory IGFBP in tissue 
culture studies, co-expression of PAPP-A in cell culture could negate this inhibitory effect. 
Furthermore, the activation of PAPP-A by IGFs suggested possible positive feedback loop 
whereby growth factor action could be enhanced. Further aspects of function, structure and 
regulation of PAPP-A activity are discussed below.  
1.5 Pregnancy associated plasma protein-A (PAPP-A) 
1.5.1 Structural Aspects 
 
Although PAPP-A was isolated over four decades ago from pregnancy serum [173] it was 
only after the cloning and expression of this large (1547-residue) protein that detailed work 
on protein structure began [174].  PAPP-A belongs to the metzincin superfamily of  metallo-
endopeptidases  containing a Zn binding motif and  highly conserved methionine residue  
[175]. PAPP-A associates with cell membranes through two of five short consensus repeat 
(SCR) modules within the C-terminus of the protein and membrane-bound PAPP-A remains 
catalytically active. This may ensure release of IGF from IGFBP-4 in the vicinity of cell 
surface IGF1R [176]. Under reducing conditions, PAPP-A migrates as a 200kDa protein 
although in pregnancy serum (and some other biological fluids) it is primarily present as a 
disulphide-bound dimer associated covalently with another disulphide bound dimer of the 
proform of  eosinophil major basic protein (proMBP) in a 2:2 heterotetrameric complex [177, 
178]. The structure of the heterotetrameric PAPP-A: proMBP complex identifies a disulphide 
bridged dimer of PAPP-A covalently bound to a disulphide bridged dimer of proMBP via two 
interchain disulphide bridges [179]. In this configuration, PAPP-A is inactive with the proMBP 
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dimer binding at or close to the active site of PAPP-A, suggesting that steric inhibition of 
enzyme activity may result. Both PAPP-A and proMBP are extensively glycosylated and 
under native gel electrophoresis conditions the complex runs as a large (>500 KDa) 
molecular weight species. A mutagenic analysis of the substrate IGFBP-4 suggested that the 
C-terminal domain of IGFBP-4 conferred the IGF dependence for PAPP-A hydrolysis of 
IGFBP-4 [180]. In addition this same study showed that the region between the Zn binding 
domain and the Met turn motif of PAPP-A was important for proteolytic activity towards the 
IGFBP-4:IGF-I complex. Availability of purified PAPP-A allowed confirmation that the rate of 
IGFBP-4 proteolysis is enhanced by binding of IGFs to IGFBP-4 [172] and  detailed kinetic 
analysis confirmed  IGF-II as a more potent activator of proteolysis than IGF-I. The effect of 
IGFs on IGFBP4 proteolysis was associated with changes in both affinity (Km) and turnover 
rate (Kcat). This study also confirmed IGFBP-5 as a PAPP-A substrate although proteolysis 
of  IGFBP5 was not IGF dependent [181].  Further mutational analysis suggested that the 
Lin12-Notch repeat (LNR) modules within PAPP-A are responsible for the differential 
requirement of IGFBP-4 and IGFBP-5 for IGF during PAPP-A mediated proteolysis [182, 
183]. 
 
1.5.2 Functional Aspects 
 
PAPP-A was partially purified from human fibroblast conditioned medium by Lawrence et al 
[184] and its identity confirmed by mass spectroscopy. By using polyclonal anti-PAPP-A 
antibodies, IGFBP4 protease activity in fibroblast conditioned medium could be completely 
inhibited, suggesting that PAPP-A may be the only IGFBP-4 protease expressed by these 
cells. PAPP-A isolated from fibroblast cultures was found to be identical to the enzyme 
described in pregnant serum [184-186], showing both IGF dependency and the same site of 
proteolytic cleavage in the central hinge domain of IGFBP-4 (see 1.4.5 IGFBP4 proteolysis). 
Identification of PAPP-A allowed some elegant transgenic studies highlighting the 
importance of this enzyme. Mice made transgenic with a col I (collagen I) promoter-PAPP-A 
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construct overexpressed PAPP-A specifically in osteoid tissue causing increased calvarial 
BMD [187]. In double transgenic mice overexpressing PAPP-A and a protease resistant form 
of IGFBP-4 (pr IGFBP-4) bone phenotype was similar to single pr IGFBP-4 transgenics, 
showing decreased calvarial thickness and BMD compared to WT mice. This provided 
strong evidence that in vivo anabolic effects of PAPP-A were due to IGFBP-4 proteolysis, 
most likely resulting in an increase in local IGF concentrations [188]. In confirmation of this, 
PAPP-A KO mice showed reduced femur BMD and blunted responses to the anabolic 
actions of parathyroid hormone (PTH) [189].In a clinical context,  PAPP-A has been 
proposed as a target for anti-proliferative therapies for cancer. Studies in an ovarian cancer 
tissue model [190] and using xenografts of adenocarcinoma A549 cells [191] showed that 
antibody mediated inhibition of PAPP-A activity decreased tumour growth presumably 
because pericellular IGF remains associated with IGFBPs leading to a reduction in free IGF 
in the local tumour environment. This may be important as current anti-IGF based strategies 
have proved disappointing in clinical trials. Anti-IGF1R strategies are hampered by 
hyperinsulinemia secondary to elevated GH levels as a result of impaired IGF-I feedback at 
the level of the pituitary [192]. This may lead to increased mitogenic signalling by elevated 
insulin levels through the insulin receptor (IR). IGF-I receptor blockade may also result in 
IGF-I signalling through the insulin receptor (IR) or through hybrid IGF1R/IR isoforms which 
are known to exist in many tissues [193]  and which may not be blocked by anti-IGF1R 
directed monoclonal antibodies (Mabs). See Yee et al [194] for an excellent review of the 
above arguments. In contrast, the use of anti-PAPP-A directed antibodies would not be 
associated with these complications acting only to inhibit IGF-I release from pericellularly 
proteolysed IGFBP: IGF complexes. The potential role(s) of PAPP-A in the aetiology of 
different cancers has been reviewed very recently [195].   
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1.5.3 Regulation of PAPP-A activity 
 
Relatively few agents have been shown to influence PAPP-A activity. IGFBP-4 proteolysis 
was inhibited following treatment of fibroblast cultures with phorbol esters. The attenuation of 
this effect by prior treatment  with actinomycin D or cycloheximide suggested Protein Kinase 
C (PKC) regulated expression of an inhibitor of IGFBP-4 proteolysis [196] Such an inhibitory 
activity was also reported in SV40 transformed hOB cells, suggesting that the process of 
cellular transformation may be associated with inhibition of IGFBP-4 proteolysis [197]. The 
finding that phorbol esters and/or SV40 mediated transformation increased the expression of 
proMBP – a covalent inhibitor of PAPP-A – suggested at least one route by which these 
agents may act to inhibit IGFBP-4 proteolysis in fibroblast cultures [198].  
An early study reported stimulation of IGFBP-4 proteolytic activity in the rat neuronal B104 
cell line by glucocorticoids [199] and following identification of PAPP-A as an IGFBP-4 
protease, the synthetic glucocorticoid dexamethasone was shown to increase enzyme 
activity in primary cultures of rat vertebral osteoblasts [200]. PAPP-A mRNA levels were not 
altered by dexamethasone treatment, suggesting a post-transcriptional mechanism by which 
enzyme activity was increased. In contrast to the above, TGFβ increased PAPP-A mRNA 
levels approximately 12-fold in hOB cultures and  this was associated with increased PAPP-
A activity in conditioned medium [201].  The demonstration of increased IGF-II mediated 
IGFBP-4 proteolysis following TGFβ treatment of hOB cultures [202] may be of particular 
significance given the fact that IGF-II and TGFβ are two of the most abundant growth factors 
present in bone matrix and a co-ordinated action of TGFβ and IGF-II in bone matrix to 
increase local availability of IGF may occur. Osteoblasts secrete IGF peptides endogenously 
(IGF-II > IGF-I) and, despite the fact that IGFBP-4 levels in osteoblast conditioned media are 
typically an order of magnitude higher that IGF-II levels, endogenous IGF-II can stimulate the 
proteolysis of concurrently expressed IGFBP-4 protein in osteoblast cultures [165, 203]. 
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Recently some novel protein inhibitors of PAPP-A activity have been described. These are 
members of the stanniocalcin family (STC1 and STC2) and were first identified as regulators 
of Ca homeostasis in teleost fish [204, 205]. However, in the context of the mammalian IGF 
axis, their status as PAPP-A inhibitors means that these proteins are negative growth 
regulators. Overexpression of STC1 or STC2 resulted in growth retardation in transgenic 
mice [206, 207], whereas KO of STC2 causes increased growth [208]. Molecular 
mechanisms of STC1 and STC2 inhibition of PAPP-A differ with STC2 forming a disulphide-
bonded covalent complex with PAPP-A and STC1 forming a high affinity non-covalent 
complex with the enzyme. Nonetheless, both STC1 and STC2 potently inhibit PAPP-A which 
may cause an increased concentration of IGF bound in complex with IGFBP-4 (and IGFBP-
5) and hence less bioavailable IGF in the pericellular environment. In agreement with this, 
STC2 inhibited PAPP-A stimulated IGF1R phosphorylation in transfected cells exposed to 
IGF-I:IGFBP4 complexes [204]. A recent study using whole exome sequencing of a large 
human cohort reported two separate single amino acid mutations of STC2 leading to 
compromised inhibition of PAPP-A. The fact that these alleles strongly associated with 
increased height in the sampled population is of particular interest [209].  A diagrammatic 
representation of the IGFBP-PAPP-A-STC axis is presented in Fig 9. 
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In the absence of STCs (upper part of Figure) cell membrane associated PAPP-A cleaves 
IGFBP-4 to release pericellular IGF-I allowing interaction of growth factor with IGF1R and 
stimulation of IGF-I mediated gene transcription. In the presence of STC1 and/or STC2, 
PAPP-A activity is inhibited, IGF-I remains bound to IGFBP-4 and IGF-I interaction with 
IGF1R is inhibited. PAPP-A is believed to associate with cell surfaces via glycosaminoglycan 
(GAG) anchors although the molecular details of this remain unresolved. 
 
 
 
 
 
 
Figure 9 The PAPP-A: IGFBP-4: STC axis. 
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1.5.4 PAPP-A in other species 
 
 PAPP-A has also been cloned from a mouse cDNA library [210].  Although murine (m) 
PAPP-A shares 91% homology with the human enzyme and cleaves IGFBP-4 in an IGF-
dependent manner, mPAPP-A activity is not elevated in pregnant serum or in placenta. In 
addition, a variant mPAPP-A containing a 29 residue insert (PAPP-Ai) was also isolated. 
Interestingly this PAPP-A isoform was a less efficient IGFBP-4 protease than the shorter 
variant of the enzyme. The significance of these differences between murine and human 
PAPP-A remains to be resolved, although PAPP-A null mice are 40% smaller than 
littermates, suggesting a role for PAPP-A during embryogenesis [211].  This may be due to  
diminished IGFBP-4 proteolysis and, therefore, reduced IGF availability in the developing 
foetus. In agreement with this IGFBP-4 proteolysis is absent in fibroblast cultures derived 
from these null mice. PAPP-A is present in multiple other species, including zebrafish and 
interestingly the absence of PAPP-A in this species causes a developmental delay which is 
independent of proteolytic activity [212].  
 
1.5.5 PAPP-A2 
 
Overgaard et al described the cloning of a metzincin protease from placental cDNA libraries 
with homology to PAPP-A. This protein, which cleaves IGFBP-5 (and IGFBP-3), was named 
PAPP-A2 [213] and  is present in human pregnancy serum where it  releases  IGF-I from 
IGF-I:IGFBP-5 complexes [214].  PAPP-A2 appears as a monomer of 200kDa in non-
reducing gel electrophoresis and in contrast to PAPP-A does not bind to proMBP or 
associate with cell surfaces. Cleavage of IGFBP-5 by PAPP-A2 is not IGF-dependent, but as 
IGFBP-5 has been reported to have both IGF-dependent and IGF-independent effects in 
hOB cultures, PAPP-A2 activity may also have major relevance in bone cell physiology. In 
agreement with this, homozygous PAPP-A2 KO mice show decreased post-natal growth 
along with reduced body length [215]. Similarly, conditional PAPP-A2 knockout in 
49 
 
osteoblasts decreased body mass and bone length, although other tissue sources of PAPP-
A2 may be involved in appropriate post-natal growth [216]. PAPP-A2  may represent a 
quantitative trait locus (QTL) regulating body shape in mice [217, 218],  Recently, two 
separate families (of Palestinian and Spanish ancestry) were found to have two different 
inactivating PAPP-A2 mutations which result in growth retardation in homozygous children 
[219]. Further analysis of affected individuals indicated significant increases of IGF-I in 
ternary ALS complexes with reduced free serum IGF-I. In addition, affected individuals 
showed moderate microcephaly, mild BMD effects and thin long bones. This phenotype was 
presumably associated with the inability of mutant PAPP-A2 to proteolyse IGFBP-3 and 
IGFBP-5 substrates. More recent in vitro and in vivo experiments in PAPP-A2 deficient 
human subjects suggests that PAPP-A2 treatment increases free IGF-I levels in these 
subjects and may constitute a novel therapeutic route for treatment of idiopathic short stature 
[220]. In this context and in analogy to PAPP-A, PAPP-A2 is also inhibited by STC-2 [205] 
and the role of the PAPP-A2: STC-2 axis in the regulation of IGF action has been recently 
reviewed [221].  
1.6 The IGF axis in dental tissue 
The limited literature in this area suggests that most components of the IGF axis are 
expressed in human dental pulp stem cells – reviewed in [222]. In a functional sense IGF-I 
has been reported previously to promote the differentiation of human dental pulp stem cells 
via mTor [223] and MAPK/Stat-3 [224] signalling pathways and there is evidence that IGFs 
which are trapped in the matrix during dentin formation  can be released into dental pulp 
following demineralisation of dentin [225-227]. In addition, IGF-I has been used as a pulp 
capping material in rat molars and enhanced reparative dentinogenesis in this experimental 
model. IGF-I increased extra-cellular matrix secretion by dental-pulp derived fibroblasts [228] 
possibly via the induction of bone morphogenetic protein (BMP)-2 expression [229]. 
Caviedes et.al demonstrated higher expression of IGF-1R in dental pulp derived from human 
teeth having incomplete roots compared with complete roots. This might be as a result of 
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increased cell proliferation during root formation and suggest a role for IGFs in this process 
[230]. In agreement with this, a very recent study used let-7c microRNA based knock down 
of IGF1R expression in DPCs to demonstrate the importance of IGF-I stimulated signalling 
pathways in the osteogenic differentiation of DPCs [231]. IGF-II was highly expressed in 
dental pulp cells isolated from deciduous teeth where the pulp was exposed during the 
removal of proximal caries compared to the level of expression in healthy premolar teeth 
[232].  IGF-II also stimulates osteotypical matrix deposition and osteodentin formation [80]. 
Both IGF-I and IGF-II (acting via the IGF-1R) can induce ALP activity in canine dental pulp 
cells [233] and IGF-II  secretion was reported during matrix mineralisation of human dental 
pulp derived fibroblasts 
With respect to other cells and tissues of the oral cavity, a detailed study of IGF axis 
expression in differentiating ameloblasts reported position specific expression of IGF-I, IGF-
II, IGF-1R and IGF-2R toward the outer enamal layer and away from pulp facing ameloblasts 
was reported arguing for the importance of the IGF axis in development of this tissue [234, 
235] and an elegent study demonstrating the developmental stage-dependent expression of 
IGF-I in the contnually erupting rat incisor model [236] also argues strongly for a role of the 
IGF axis in the development of dental tissues. IGF-I induces the accumulation of amelogenin 
and ameloblastin suggesting that this growth factor plays a role in enamel bio-mineralization 
as ameloblasts also express IGF-1R [237]. A very recent study using stem cell populations 
isolated from apical papillae (SCAP) reported the stimulation of cell proliferation, ALP 
expression and mineralisation activity by IGF-I. Simultaneously, expression of odontogenic 
markers (dentin sialoprotein and dentin sialophosphoprotein) was down regulated arguing 
for a bias in IGF-I action toward bone formation and away from odontogenic differentiation in 
this tissue niche [238, 239].  Gotz et al. (2001) demonstrated the expression of IGF axis 
components during reparative processes in periodontal connective tissue with IGF axis 
proteins found in both the cellular and acellular compartments of extrinsic fibres of 
cementum. In addition cementoblasts and periodontal ligament fibroblasts  express IGF-1R 
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and these findings confirm to some extent previous reports of an association between 
mineralised nodule formation and increased expression of IGF-1R [240]. As IGFII has been 
reported to be expressed at moderate to high levels in our experiments and in previous 
reports [241] this suggests that both IGF-I and IGF-II  may be available locally to act through 
the IGF1R [242, 243]. This is also in accord with the observation that IGF-II and IGF-II along 
with all six IGFBPs are present in the ECM of the periodontal ligament and IGF-1R is 
present on the surface of periodontal ligament derived fibroblasts [244]. Finally, microarray 
analysis indicated an 8-fold increase in IGFBP-5 expression in DPCs derived fron non-
carious wisdom teeth following 10 days treatment with mineralisation medium although this 
group did not confirm IGFBP-5 protein expression [39, 245].  
Dental tissues develop from oral ectoderm and neural crest derived mesenchyme and 
contain pluripotent stem cell populations which display a developmental potential similar to 
embryonic stem cells (ESCs)[18, 246] . Dental pulp tissue represents an accessible source 
of such cells and hDPCs have been extensively used in various cell differentiation studies 
[29, 47, 247] . Undifferentiated cells display a fibroblast-like morphology with associated high 
efficiency for adherent colony formation and high proliferative potential[248]. These 
properties suggest that adult dental tissues may provide a source of material (often 
discarded in the clinic) to provide multipotent cells for subsequent tissue engineering studies. 
To date the main use of such cells has been in hard tissue engineering programmes with a 
view to treatment of dental trauma. As such hDPCs have been differentiated down 
osteogenic/odontogenic lineages to generate appropriate 3-dimensionalbone and or dentin 
structure [245, 249]. Although such strategies have met with some limited success, they are 
hampered by an inadequate understanding of the effects of local growth factors on dental 
pulp cell differentiation. In the context of osteogenesis, the IGF axis is known to play a 
crucial role in both the maintenance and differentiation of bone tissue [1]. Similarly, some 
recent studies have suggested a role for IGFs in regulating osteogenic/ odontogenic 
differentiation of hDPCs [223, 250] although the majority of these studies have given little 
attention given to the role of IGFBPs in this process. Therefore, in the current study we have 
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used the hDPC culture model to report comprehensively on IGF axis expression and activity 
during the osteogenic differentiation of these cells. In addition, we investigate the activity of 
the specific IGFBP-4 proteinase (PAPP-A), which is expressed as the sole IGFBP-4 
protease by hDPCs, and the potential regulation of PAPP-A activity by stanniocalcin-2 
(STC2) a recently described proteinase inhibitor of PAPP-A. We describe a series of co-
ordinated changes in IGF axis expression which we suggest may represent part ofan 
“osteogenic signature” associated with differentiating hDPCs. 
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1.7 Aims & Objectives 
Aim 
 
To investigate the basal expression of components of the IGF-axis which are 
potentially implicated in regulating dental pulp cell osteogenic differentiation. 
 
Objectives 
 
• to investigate expression of IGFs, IGFRs and IGFBP mRNA in DPCs. 
• to investigate IGF and IGFBP expression at protein level 
• to investigate changes in IGF and IGFBP expression during osteogenesis 
• to investigate activity of IGFs in differentiating DPCs 
• to investigate the action of selected IGFBPs on IGF activity 
• to examine IGFBP-4 and IGFBP-5 proteolysis in DPCs 
• to examine the potential role of PAPP-A in IGFBP-4 proteolysis in DPCs 
• to examine a potential regulation of PAPP-A activity by STC-2 in DPCs 
• to examine membrane association of PAPP-A in DPCs 
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Chapter 2 Materials & Methods 
2.1 Materials 
Table 1 Material used in all experimental workTable 
 
 Material supplier Catalogue no 
General 
laboratory 
material 
Alpha-Modified Minimum 
Essential Medium (α-MEM) 
 
BioWhittaker, UK. 
 
BE17-516F 
 
 Phosphate buffered saline 
(PBS) 
 
BioWhittaker, UK. 
 
BE12-169F 
 
 Penicillin/Streptomycin 
(Pen/Strp)  
 
Sigma-Aldrich, UK. 
 
P4333 
 
 foetal bovine serum (FBS) 
 
Sigma-Aldrich, UK. 
 
F9665 
 
 L-glutamine 
 
Sigma-Aldrich, UK. 
 
G7513 
 0.25% (w/v) Trypsin-EDTA   
solution 
 
Sigma-Aldrich, UK. 
 
T4049 
 
 Trypan blue solution, 0.4% 
(w/v) 
 
Sigma-Aldrich, UK. 
 
T8154 
 
 Dimethylsulfoxide (DMSO) 
 
Sigma-Aldrich, UK. 
 
276855 
 
 dexamethasone,  
 
Sigma-Aldrich, UK. 
 
31375 
 
 L-ascorbic acid  
 
Sigma-Aldrich, UK. 
 
A4403 
 
 Naphthol AS-MX 
phosphatase solution 0.25% 
(w/v) 20mL 
 
Sigma-Aldrich, UK. 
 
855 
 
 Collagenase type I  
 
ThermoFisher scientific 
 
17100-017 
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 Dispase II neutral protease, 
grade II  
 
Sigma-Aldrich, UK. 
 
4942078001 
 
 15mL centrifuge tubes  
 
Corning®, UK. 
 
430790 
 
 50mL centrifuge tubes,  
 
Corning®, UK. 
 
430828 
 
 T-25 cm2 tissue culture 
flasks  
Corning®, UK. 
 
430639 
 
 T-75 cm2 tissue culture 
flasks 
Corning®, UK. 
 
430641 
 
 T-175 cm2 tissue culture 
flasks 
 
Corning®, UK. 
 
#431080 
 
 10cm Petri dishes 
 
Corning®, UK. 
 
353803 
 
 6 well tissue culture plates  Starlab UK 18341 
 
 Syringes 
 
TERUMO, UK 
 
05SE1 
 
 Syringe filters Sartorius - UK 16532 
 
 70μm strainer  
 
Falcon, USA 352350 
 
 Pasteur pipettes  
 
SS Scientific lab 
supply, UK 
PIP4105 
Alizarin Red 
staining  
Alizarin Red staining 
quantification assay 
 
ScienCell, UK 8678 
Qrt-PCR RNeasy® mini kit   Qiagen, UK 74104 
 
 β-mercaptoethanol  
 
Applichem, UK A4338 
 Absolute ethanol (200 Proof, 
Molecular  
Scientific Laboratory 
Supplies Ltd, UK 
BP2818-500 
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Biology Grade) 
 
 TaqMan probes (see 
Supplementary 1 for further 
information) 
 
  
 Ultrapure DNAse/RNase-free 
distilled water  
Thermo Fisher 
Scientific, UK 
10977035 
 
 RNase-free tubes Thermo Fisher 
Scientific, UK 
AM12400 
 
 Lens cleaning tissue Thermo Fisher 
Scientific, UK 
FB13067 
 DNase I Amplification  
 
Invitrogen, UK 18068015 
 
 Optical adhesive seal  
 
Geneflow Ltd, UK P3-0300 
 
 High Capacity RNA to cDNA 
kit 
Applied Biosystems 
(ABI), UK 
4387406 
 
 master mix  
 
Applied Biosystems 
(ABI), UK 
 
4369016 
 
 PCR tubes (0.2mL flat cap)  Bio-Rad, UK. TFI0201 
 
 
 Non-stick RNA-free 1.5mL 
microfuge tubes  
Ambion ®, Mexico 
 
AM12450 
 96 well PCR microplates Starlab, USA I1402-9909 
 
 PTC-100 Peltier -version 9 MJ Research 2030882 
 Roche LC480 Light Cycler 
was used to generate data 
 
Roche 05015243001 
 
Western blot 
And ELISA 
Precision Plus Protein™ 
WesternC™ Blotting 
Standards, 250 µl  
BioRad, UK 1610376 
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 Precision Protein 
Streptavidin-HRP, 125 ul 
BioRad, UK 1610381 
 
 Pierce LDS Sample Buffer 
(non-Reducing) (4X)  
 
BioRad, UK 84788 
 
 10x Tris-buffered saline 
(TBS) 
 
BioRad, UK 1706435 
 
 10x Tris/Glycine/SDS, 1 L  
 
BioRad, UK 1610732 
 
 Restore™ PLUS Western 
Blot Stripping Buffer 
 
BioRad, UK 46430 
 
 Mini-protein® TGX stain-free 
gels, 8-16% (30 µl)  
 
BioRad, UK 4568103 
 Mini-protean® TGX stain-
free™ gels 4 -15% (30 µl)  
 
BioRad, UK 456-8083 
 
 Trans-Blot Turbo transfer 
pack (PVDF) 7x 8.5cm 
 
BioRad, UK 1704156 
 
 Trans-Blot® Turbo transfer 
system (transfer pack mini 
format 69 BR007547)  
 
BioRad, UK 1704150 
 ChemiDoc imager 
 
BioRad, UK. Version 6 
 Tween® 20 Fisher Scientific Ltd, 
UK 
BPE337-500 
 Bovine albumin Faction V  
 
MP Biomedicals, UK 160069 
 Tergitol solution type NP-40 
70% solution  
 
Sigma-Aldrich, UK NP40S-1 
 
 Corning gel-loading tips 
(0.2MM)  
Sigma-Aldrich, UK CLS4884-400EA 
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 Human IGFBP-4 Antibody 
(Antigen Affinity-purified 
Polyclonal Goat IgG)  
 
R&D Systems, UK AF804-SP 
 Human IGFBP-5 Antibody 
(Antigen Affinity-purified 
Polyclonal Goat IgG) 
 
R&D Systems, UK AF875-SP 
 
 Donkey Anti-Goat IgG HRP 
Affinity purified Secondary 
Antibody  
 
R&D Systems, UK. HAF109 
 
 Anti-STC2 antibodies at 1 
µg/mL. 
 
R&D Systems, UK. AF2830 
 
 Polyclonal swine anti-rabbit 
IgG-HRP  
 
R&D Systems, UK. P0217 
 
 Polyclonal rabbit anti-goat 
IgG-HRP 
 
Dako 
 
P0160 
 
 Super-Signal® West Femto 
Maximum Sensitivity 
Substrates   
 
Fisher scientific, UK. 
 
34095 
 
 Round gel-loading tips  
 
Starlab, UK 
 
I1022-0810 
 
 3-8% Tris-acetate gradient 
SDS-PAGE gels were from 
Novex, Life Technologies. 
 
Novex, Life 
Technologies. 
 
EA0375PK2 
 
 PVDF membranes 
 
Millipore 
 
IPVH00010 
 
  
ImageQuant LAS 4000 
instrument  
(Images were captured and 
quantitated) 
 
 
GE Healthcare 
 
 
LAS 4000 
 
 IGFBP-2 (DuoSet) ELISA 
 
R&D Systems, UK. 
 
DGB200 
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 IGFBP-3 (Quantikine) ELISA 
 
R&D Systems, UK. 
 
DGB300 
 
 IGFBP-4 (DuoSet) ELISA 
 
R&D Systems, UK. 
 
DY804 
 
 IGFBP-5 (DuoSet), ELISA 
 
R&D Systems, UK. 
 
DY875 
 
 IGFBP-6 (DuoSet), ELISA 
 
R&D Systems, UK. 
 
DY876 
 
 IGF-I (Quantikine) ELISA 
 
R&D Systems, UK. 
 
DG100 
 
 IGF-II Quantikine ELISA  
 
R&D Systems, UK. 
 
DG200 
 
 STC2 (DuoSet) ELISA 
 
R&D Systems, UK. 
 
AF2830 
 
 Human PAPP-A (Quantikine) 
ELISA 
 
R&D Systems, UK. 
 
DPPA00 
 
 
 Wash buffer  
 
R&D Systems, UK. 
 
WA126 
 
 Reagent Diluent 
 
R&D Systems, UK. 
 
DY004 
 
 normal goat serum  
 
R&D Systems, UK. 
 
DY005 
 
 streptavidin- horseradish 
peroxidase (HRP)  
R&D Systems, UK. 
 
890803 
 
 Substrate Solution: colour 
reagent A (H2O2), colour 
reagent B 
(Tetramethylbenzidine)  
 
R&D Systems, UK. 
 
DY999 
 
 stop solution -2 N H2SO4  
 
R&D Systems, UK. 
 
#DY994 
 
 The 96 well ELISA plates  Starlab, UK. 
 
S1837-9600 
 
 Varioskan Flash type 300 
spectrophotometer 
(for absorbance 
determination) 
Thermo-Scientific 
 
300 
spectrophotometer 
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Alkaline 
phosphatase 
assay 
 
p-nitrophenol Alkaline buffer 
solution 100mL 
Sigma-Aldrich, UK. 
 
100-02-7 
 
 p-Nitrophenyl Phosphate 
Liquid 
Sigma-Aldrich, UK. 
 
A9226 
 
 Substrate System Sigma-Aldrich, UK. 
 
N7653 
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2.2 Methods 
2.2.1 Isolation of dental pulp stromal cells  
 
Healthy third molar teeth were used to study the expression of IGF axis components under 
basal conditions and during differentiation of dental pulp stromal/stem cells (DPSCs) into 
osteogenic lineages. Freshly extracted healthy fully erupted third molars were collected from 
adult patients (20-40 years of age) at the outpatients’ dental clinic of Leeds Dental Institute. 
Teeth were obtained through Leeds Dental and Skeletal tissue bank (LDI Research Tissue 
Bank; 200116/1/a), with patients’ informed consent. The age and gender of patients were 
recorded (Table 2). External tooth surfaces were washed using sterile PBS and surrounding 
soft tissue attachments were removed using a sterile scalpel. External tooth surfaces were 
washed again with sterile PBS and were cracked open using a decontaminated device to 
access the pulp tissue. Pulp tissue was gently separated by sterilized tweezers from the 
crown and root chambers, avoiding the apical third of the pulp tissue to prevent cross 
contamination with periodontal tissues. Isolated tissues were minced using a sterile scalpel 
before being digested in a solution of 5mL α-MEM, 3mg/mL collagenase type I and 4mg/mL 
dispase. The tissue- enzyme mixture was incubated for 1 h at 37° C and was continuously 
mixed using a shaker inside the tissue culture incubator. The tissue-enzyme mixture was 
regularly checked at 15 min intervals to avoid over-digestion. The enzymatic reaction was 
stopped with 20% (v/v) FBS after complete dissociation of the pulp tissue. Cell pellets were 
obtained by centrifugation at 1000 g for 10 minutes. The supernatant was carefully aspirated 
and discarded. The pelleted cells were re-suspended in proliferation medium consisting of α-
MEM, supplied with 20% (v/v) FBS, 100 unit/mL Pen Strep, and 200mM L-glutamine. The 
cell suspension was passed through a 70μm strainer and seeded into T-25 cm² flask and 
15cm Petri dish. The cultures were incubated at 37°C and 5% CO2 in proliferation medium. 
 
 
62 
 
                   Table 2 Details of all donors used in the current study  
 
Donor Age Gender tooth Type 
H1 20 Female Third molar 
H2 35 Female Third molar 
H3 24 Female Third molar 
We were obviously restricted in teeth selection by those donors which were available at the 
Leeds Dental Institute during the time of this study. 
 
2.2.2 Cell culture and expansion 
 
Isolated DPSCs were sub-cultured in T-175 cm² flasks, and media were changed every 5 
days until cells reached 80% confluence. Monolayers were then washed with sterile cold 
PBS and detached using 0.25% (w/v) Trypsin-EDTA solution for 5 minutes. Twenty percent 
FBS was added to neutralize the trypsin, and then the cell suspension was transferred to a 
50mL universal tube and centrifuged at 1100 g for 5 minutes. The supernatant was 
discarded, and the cell pellet was re-suspended in fresh proliferation media and cultured in 
the tissue culture flasks or plates according the experimental requirements. Cells were 
counted using a haemocytometer after staining with 0.01% (w/v) Trypan blue to exclude 
dead cells. Cells were seeded with the required densities according to the experimental plan. 
 
2.2.3 Osteogenic differentiation of DPSCs  
 
hDPSCs at passage 4 were cultured in 6-well plates at 1X105 cells/well under basal 
conditions (α-MEM supplemented with 20% (v/v) FBS, 200mM L-glutamine, and 100unit/mL 
Pen Strep). When the cells reached 80% confluence, they were cultured in triplicate under 
basal or osteogenic conditions (basal medium + 10nM dexamethasone and 100μM of L-
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ascorbic acid). Cultures were terminated at 1 and 3 weeks for further investigation of 
changes in gene expression using qRT-PCR for detection of relative changes in the 
expression of changes in the IGF axis gene expression. Histological staining (Alkaline 
Phosphatase (ALP) and Alizarin red stains), as well as IGF protein expression were also 
investigated. Experiments were performed on cells derived from three healthy donors and 
triplicate wells were used for each time point and each culture condition; basal and 
osteogenic. 
 
2.2.4 Gene expression 
 
2.2.4.1 mRNA extraction 
 
DPCs cultured for 1 and 3 weeks under basal and osteogenic conditions were detached as 
described above and counted to determine the amount of cell lysis buffer required. mRNA 
extraction was performed according to manufacturer’s instructions using Qiagen RNAeasy® 
min kit summarised in Table 3. 
2.2.4.2 mRNA quantification 
 
A NanoDrop spectrophotometer (ND 1000) was used to quantify the yield and purity of 
mRNA. 2 μl of the extracted mRNA was used and quantities were recorded as ng/μl. 
A260/280 ratios were also recorded as an indication of mRNA purity and were typically 1.8 - 
2.0 indicating acceptable purity. 
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Table 3 RNA extraction using RNAeasy mini kit 
 
Reagents 
The amount needed to perform the 
reaction 
Buffer RLT 
1- Add sufficient buffer RLT and mix. 
2- Transfer lysed cells to nuclease 
free Eppendorf and mix on the vortex 
for 1 min. 
3- Add 70% ethanol at 1:1 (v/v) with 
buffer RLT 
4- Transfer up to 700μL of the mix to 
RNAeasy spin column placed in 2mL 
collection tube 
Number of pelleted 
cells 
Volume of 
buffer RLT (μl) 
˂ 5 X 106 350 
5 X 106   to 1 X 107 600 
More than 1 X 107 Not suitable 
5- Add RW1, centrifuge, and discard 
the flow through. 
700μL 
6- Add buffer RPE, centrifuge, and 
discard the flow through. 
7- Repeat step no. 6 and use new 
collection tube. 
500μL 
8- Add nuclease free water, 
centrifuge and collect the RNA elutes 
in a new tube. 
30μL 
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2.2.4.3 DNase purification  
 
To ensure that the mRNA was pure and clear of any genomic DNA, DNase I amplification 
grade kit was used according to the manufacturer’s instructions. Briefly, a mixture of DNase I 
buffer, enzyme, and mRNA sample (up to 1μg) were mixed in a 10μL reaction volume and 
incubated at room temperature for 15 minutes. The reaction was stopped by adding 1μL 
EDTA to the mix, then incubating at 65°C for 10 minutes in the PTC-100 thermal cycler. 
2.2.4.4 Reverse transcription  
 
 Reverse transcription was carried out to generate single stranded cDNA from the mRNA by 
preparing 20μL reaction volume using the ABI high capacity RNA to c-DNA kit. Briefly, 10μL 
of buffer were added to 1μL of enzyme, and 9μL of mRNA sample, and then incubated in the 
PTC-100 thermal cycler for 1 hour at 37°C followed by 5 minutes at 95°C. Negative controls 
for the experiment were generated during this step, by removing the mRNA template in one 
reaction and reverse transcriptase enzyme in the other. 
2.2.4.5 qRT- PCR 
 
Quantitative real time PCR was performed using a Roche LC480 light cycler. The 
experiment was performed in a 20μL reaction volume composed of 10μL gene expression 
master mix, 1μL Taqman gene expression assay specific for each gene, 8μL nuclease free 
water and 1μL c-DNA sample. The 20μL mix was added into each well of 96 well PCR 
reaction plate in triplicate. In addition, triplicates of non-template negative control and RT 
negative control were included in each plate. The plate was sealed securely and centrifuged 
for 10 second before starting the amplification procedure using the light cycler. Amplification 
was carried out according to Applied Biosystems (AB) recommendations for Taqman® 
probes. 
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            Figure 10 Details of qRT-PCR amplification program 
             
 
Taqman gene expression assay identifiers are presented in Appendix Table I. 
 
 
 
 
 
 
1st 
•Pre-incubation cycle:
• 5 minutes at 95 ºC
2nd
•45 amplification cycles compising of:
•1- 95 ºC for 5 seconds
•2- 65 ºC for 1 minutes
3rd
•Final cooling:
•40 ºC for 30 seconds
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2.2.4.6 Data analysis  
 
For each gene, relative expression levels were calculated using the 2-ΔΔCt method [251, 252]. 
In brief, the threshold cycle (Ct) value was determined for each gene of interest in triplicate. 
Technical replicates were averaged, and then normalized to that of the house-keeping gene 
GAPDH. This is referred to as the ΔCt value. The ΔΔ Ct values were determined by 
normalizing the ΔCt value for each treated sample (under osteogenic conditions) to the 
appropriate control samples (under basal conditions) at each time point to be able to 
determine the relative changes in gene expression of IGF axis following osteogenic induction 
of DPCs. The relative changes in gene expression were calculated using the 2-ΔΔct equation. 
In all cases, the 2-ΔΔct values for all markers were compared in DPCs. Changes in the gene 
expression levels were plotted as 2-ΔΔct ± SD. 
 
2.2.5 Protein expression 
 
 DPCs were cultured under both basal and osteogenic conditions for 1 and 3 weeks as 
described previously, changing media was performed once every week. One mL of 
conditioned medium was collected from each medium change and was either freeze-dried 
and stored at -20ºC or directly stored at -80ºC without freeze-drying. 
2.2.5.1 Western blotting 
 
In western blotting, 1mL of medium conditioned by DPCs cultured under basal and 
osteogenic conditions was collected, and freeze-dried. Freeze-drying is a process used to 
remove the water from the sample by freezing then drying it under a vacuum at very low 
temperatures. Powdered media were then dissolved in 4X SDS-polyacrylamide (SDS-
PAGE) sample buffer containing β-mercaptoethanol (1:20, v/v) and loaded onto 4-15% (w/v) 
SDS-polyacrylamide pre-cast gels (30μL /well). Suitable molecular weight markers (5µL of 
dual colour standards, 10 -250 kDa) were loaded in a lane next to the samples to be able to 
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determine molecular weight of the target proteins. Gels were run at 120V for 1 hour then 
proteins were transferred to PVDF semi dry membranes using the Trans-Blot Turbo device 
(BioRad) for 10 minutes. After blotting, the membrane was rinsed three times with distilled 
water (dH2O) and incubated for 1hour with gentle agitation at room temperature in blocking 
solution, which comprised 5% bovine serum albumin (BSA) in Tris-buffered saline containing 
Tween-20 (TBS-T, 0.05%, v/v). After blocking, the membrane was washed three times for 5 
minutes using 0.05 (v/v) TBS-T then incubated overnight at room temperature with one of 
the following primary antibodies: anti- IGFBP-4 or anti-IGFBP-5 reconstituted (1:1000, v/v) in 
0.05% (v/v) TBS-T. Next day, the membrane was washed three times for 5 minutes using 
0.05% (v/v) TBS-T then incubated with the appropriate streptavidin horseradish peroxidase 
(HRP) conjugated secondary antibody reconstituted (1:10000, v/v) in 5% (w/v) BSA in 0.05% 
(v/v) TBS-T for 1 hour with gentle agitation at room temperature. After that, the membrane 
was washed three times, each for 15 minutes using 0.05% TBS-T, and was developed with 
ultra-sensitive enhanced chemiluminescent (ECL) substrate (A and B, 1:1 v/v) and images 
were obtained and recorded on the ChemiDoc imager. 
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2.2.5.2 Enzyme-linked immunosorbent assay (ELISA) 
DPCs were grown under basal and osteogenic conditions for 1 and 3 weeks. Conditioned 
medium (1mL) was collected from each culture at 1 and 3 week time points under basal and 
osteogenic conditions. IGFBP(2,3,4,5,6), IGF-I, IGF-II, STC2 and PAPP-A concentrations in 
conditioned media were determined by ELISA using human IGFBP-2 Duo Set ELISA kit , 
human IGFBP-3 Quantikine ELISA Kit, human IGFBP-4 Duo Set ELISA kit, human IGFBP-5 
Duo Set ELISA kit, human IGFBP-6 Duo Set ELISA kit,  human IGF-I Quantikine ELISA Kit, 
human IGF-II Quantikine ELISA Kit, human stanniocalcin 2 ELISA kit and Human PAPP-A 
Quantikine ELISA kit according to the manufacturer’s protocol. Briefly, capture antibody 
(mouse anti-human) was diluted at 2μg/mL for IGFBP-2 and at 4μg/mL for IGFBP-4, 5 and 
6) and for STC2 was diluted at 7.5μg/mL in PBS was plated in 96 well microplates 
(100μL/well) and incubated overnight at room temperature. On the following day, the plate 
was washed with 300μL of 1:25 (v/v) diluted washing buffer (0.05% (v/v) Tween-20 in PBS) 
four times. Plates were blocked using 300μL of the 1:5 (v/v) regent diluent (5% (v/v) Tween -
20 in PBS, 0.2µm filtered) and incubated for 1 hour at room temperature. After washing four 
times with 400μL washing buffer, 100μL of the samples, and appropriately diluted standards 
were added to the previous 96 well plate and incubated for 2 hours at room temperature. 
Plates were washed as above and 100μL of the detection antibody (biotinylated goat anti-
human IGFBP2, 4, 5, 6 and STC2) were added at 200ng/mL in reagent diluent with 2% (v/v) 
heat activated goat serum for 2 hours at room temperature. After washing, 100μL of working 
dilution of streptavidin-HRP (1:200, v/v) was added for 20 minutes and plates were 
incubated at room temperature in the dark. Finally, plate was washed and 100μL of 
substrate solution (colour reagent A: H2O2 and colour reagent B: Tetramethylbenzidine, 1:1 
v/v) were added and the plate was incubated for 20 minutes at room temperature in dark. 
50μL of stop solution (2 N H2SO4) was added and absorbance was determined immediately 
using a microplate reader (Thermo-Scientific Varioskan Flash type 300 spectrophotometer) 
at 450nm. 
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For IGFBP-3, IGF-I, IGF-II and PAPP-A, the Quantikine ELISA kit was used. The assay was 
performed following the manufacturer’s instructions. In brief, 100µL of assay diluent for 
(IGFBP-3: RD1-62, IGF-I: RD1-53 and PAPP-A: RD1-15) was plated in a 96 well plate. Next, 
100μL of the samples, and appropriately diluted standards in calibrator diluent for (IGFBP-3: 
RD5P, IGF-I: RD5-22, IGF-II: RD5-42 and PAPP-A: RD6-14) were added to the assay 
diluent and incubated for 2 hours at 2-8ºC. The plate was washed with 400μL of 1:25 (v/v) 
washing buffer (buffered surfactant) three times. Then for IGFBP-3, 200µL of chilled IGFBP-
3 polyclonal anti-IGFBP-3 HRP conjugate was added per well and incubated for 2 hours at 
2-8ºC, for IGF-I, It was 200µL of chilled human IGF-I conjugate added per well and 
incubated for 2 hours at 2-8ºC, for IGF-II, 200μL of Human IGF-II Conjugate to each well and 
covered with a new adhesive strip then Incubate for 2 hours at room temperature on the 
shaker, for PAPP-A, 200μL of Human PAPP-A Conjugate added to each well and covered 
with adhesive strip then Incubate for 2 hours at room temperature. The plate was washed as 
above and 200µL of substrate solution were added per well (colour reagent A: stabilized 
H2O2, colour reagent B: stabilized Tetramethylbenzidine, 1ː1, v/v) and incubated for 30 
minutes at room temperature in the dark. Finally, 50μL of stop solution (2 N H2SO4) was 
added and absorbance was determined immediately using a microplate reader at 450nm. All 
ELISA assays were specific as reported on suppliers product information sheets (see the 
following websites for the following products from R&D Systems, UK.) 
https://www.rndsystems.com/products/human-igfbp-2-quantikine-elisa-kit_dgb200 
https://www.rndsystems.com/products/human-igfbp-3-quantikine-elisa-kit_dgb300 
https://www.rndsystems.com/products/human-igfbp-4-duoset-elisa_dy804 
https://www.rndsystems.com/products/human-igfbp-5-duoset-elisa_dy875 
https://www.rndsystems.com/products/human-igfbp-6-duoset-elisa_dy876 
https://www.rndsystems.com/products/human-igf-i-igf-1-quantikine-elisa-kit_dg100 
https://www.rndsystems.com/products/human-igf-ii-igf2-quantikine-elisa-kit_dg200 
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https://www.rndsystems.com/products/human-stanniocalcin-2-stc-2-antibody_af2830 
https://www.rndsystems.com/products/human-pappalysin-1-papp-a-quantikine-elisa-
kit_dppa00 
 
2.2.6 In vitro bioassay  
 
DPCs were grown to 80% confluence to examine the effect of IGF by incubating cells with 
and without adding (100nM) of IGF-I for 14 days in both basal and osteogenic conditions. 
Then, cells incubated in basal and osteogenic medium with a fixed concentration of IGFBP-4 
and IGFBP-5 at (10nM), and varying concentrations (0nM, 1nM, 10nM, 100nM) of IGF-I. 
Medium was changed at day 4, 7, 10, 13, 17 and cultures were terminated at day 21.  
ALP enzyme activity has been examined as an osteogenic marker. Alkaline phosphatase 
activity was measured by the ability of alkaline phosphatase enzyme to convert the 
colourless substrate para-nitrophenylphosphate (pNPP) into yellow para-nitrophenyl (pNP) 
as previously described [253]. Briefly, Cells were washed twice with PBS, and lysed by 
200µL of 0.1% (v/v) Triton™x-100 followed by three cycles of freezing and thawing. Lysates 
were centrifuged (1000g) for 5 minutes and 20µL of the supernatants were used in ALP 
activity assay. Standards were prepared by diluting pNP in buffer, provided with the pNPP 
substrate as a kit, at concentrations of 5, 25, 50, 100, 150 and 200 nmol/mL. A 100μL of 
each standard was added to the wells of a 96 well plate (n=3). A 90μL of pNPP substrate 
was then added to 10μL of sample lysates in triplicates in 96 well plate. The plate was then 
incubated at 37 ºC for 30 minutes in dark. The reaction was stopped by adding 100μL of 1M 
NaOH. The sample absorbance was measured at 405nm using a microplate reader. Alkaline 
phosphatase specific activity was expressed as nanomoles of p-nitro phenol/µg DNA.  
For Alizarin red s staining quantification assay, calcium deposits were evaluated in 
cell culture by examining the effect of IGF through incubating cells in both basal and 
osteogenic conditions with and without adding (100nM) of IGF-I for 14 days. Cells 
72 
 
were washed 3 times with PBS. 4% formaldehyde was used to fix cells for 15 
minutes at room temperature. Then cells were washed 3 times with distilled water. 
After removal of distilled water, 1mL of Alizarin red stain was added for each well 
and incubated for 20-30 minute at room temperature with gentle shaking. The cells 
were washed 5 times with dH2O after dye removal and stored at -20°C before dye 
extraction. 200 μL of 10% acetic acid were added to each well and incubated for 30 
min at room temp with shaking then cells were collected using scraper and 
transferred to a 1.5-mL microcentrifuge tube and vortexed for 30 sec. Samples were 
heated at exactly 85°C for 10 minutes and incubated for 5 min on ice then 
centrifuged for 15 min. After centrifuging, 200μL of supernatant were transferred to 
new tubes and 75μL of 10% ammonium hydroxide were added to neutralize the acid. 
Finally, 50 μL/well of samples and standards were added in triplicate on a 96-well 
plate (opaque-walled, transparent-bottomed plates) and then, the absorbance at 405 
nm with a plate reader was recorded. 
 
2.2.7 In vitro IGFBP proteolysis 
 
I-IGFBP-4 (10nM) and IGF-I (100 nM) were incubated with 20 pM recombinant PAPP-A 
(rPAPP-A) or basal/osteogenic CM containing an equivalent concentration of PAPP-A 
(determined by ELISA see Fig20) at 37C in a medium of 2mM CaCl2/50 mM Tris pH 7.5. 
Total assay volume was 25ul. Inhibitory anti-PAPP-A monoclonal antibody (1/41) or control 
monoclonal IgG1 (both 20 nM) were present when required. Reactions were terminated after 
6hr by the addition of x1 non-reducing SDS sample buffer. Following electrophoresis through 
12% polyacrylamide SDS-PAGE gels levels of intact and fragmented IGFBP-4 determined 
by direct autoradiography as previously described [184]. Details of 125I-labelled IGFBP-4 
proteolysis assay have been published previously [181].   
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2.2.8 Immunoprecipitation and WB  
 
Immunoprecipitation (IP) of PAPP-A and STC2 from human SMC conditioned media was 
performed by incubation (4°C, 16 h) of 500 µl medium with 15 μl protein G-Sepharose 4 Fast 
Flow beads (GE Healthcare) cross-linked to PAPP-A-specific mAb PA11 or mAb STC221 
respectively, in a total volume of 1 mL. Beads cross-linked to irrelevant IgG2a served as a 
control. Antibodies were immobilized at 2 mg/mL by using dimethyl pimelimidate 
dihydrochloride (Sigma) cross-linking [184] After three washes in 20 mM NaH2PO4, 500 mM 
NaCl, 0.01% Tween 20, pH 7.4, precipitated protein was eluted with 0.1 M glycine pH 2.0. At 
the end of all steps, beads were centrifuged at 3,000 ×g for 5 min. Bound protein was eluted 
into non-reducing SDS sample buffer. Eluted protein was analyzed by Western blotting. 
Briefly, proteins were separated by 3-8% Tris-acetate or 12% Tris-glycine SDSPAGE and 
blotted onto PVDF membranes. After blocking with 2% Tween 50mM Tris-HCl,500 mM NaCl 
(pH7.5) for 5 min, membranes were incubated overnight at rom temp with polyclonal rabbit 
anti-PAPP-A [178]or polyclonal goat anti-STC2 at 1 µg/mL. Antibodies were diluted in 2% 
skimmed milk powder in 50 mMTris-HCl,500 mM NaCl, 0.1% Tween 20, pH 9.0 (TST). 
Membranes were subsequently incubated (30 min) with polyclonal swine anti-rabbit IgG-
HRP or polyclonal rabbit anti-goat IgG-HRP diluted 1:2000 in 2% skimmed milk powder in 
TST, and then developed by enhanced chemiluminescence (ECL Prime, GE Healthcare). 
Images were captured using an ImageQuant LAS 4000 instrument (GE Healthcare). 
Between the steps, membranes were washed in TST three times. Recombinant PAPP-A, 
STC2, and the PAPP-A: STC2 complex used for control were generated as described 
previously [204, 254]. Details of the IP/WB methods have been published previously in the 
supplementary material to ref [255]. 
 
 
74 
 
2.2.9 Statistical analysis  
 
All experiments were carried out in triplicate from three different donors in each 
group; DPCs. ELISA and qRT-PCR results were analysed using students t-test and 
one way analysis of variance (ANOVA) followed by Bonferroni multiple comparison 
tests. P-values were determined, and P<0.05 was considered significant. The 
statistical analyses were carried out using the GraphPad Prism software (v-6). ……
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Chapter 3: IGF axis expression and activity in DPSCs 
3.1 Introduction 
We have previously partially characterised IGF axis expression and activity in DPCs. in this 
section we confirm our previous observations and extend our studies to accurately quantify 
IGF axis genes at both the mRNA and protein level using qRT-PCR and ELISA respectively 
[1, 2]. 
3.2 qRT-PCR 
We used TaqMan based qRT-PCR to quantify relative expression of IGF axis genes. 
Previous studies have established that 7 day and 21 day time points were appropriate to 
study IGF axis gene expression in hDPCs ( see figure 2 in [1]). 
 Expression was expressed relative to GAPDH housekeeping gene using the ΔCt method 
(see Methods 2.2.4.6). In Fig 10 we show data obtained for IGF axis expression following 
culture of DPCs for 1wk under basal conditions. These data show that all IGF axis genes, 
with the exception of IGF-I and IGFBP-1 were expressed in DPCs under our culture 
conditions. The fact that IGF-II is the main growth factor expressed by DPCs has important 
implications and we return to subject in the Discussion section of this Chapter. In terms of 
abundance of IGFBP expression we found that the following order BP4>BP5>BP-6 ~ BP-2 > 
BP-3 was repeatedly seen – note the logarithmic axis of Figure 10. We found that IGF1R 
and IGF2R were expressed at approximately the same level, although we present evidence 
later in this section that in common with most cell types IGF1R is the active IGFR in DPCs. 
With raw Ct values for those genes expressed at 15-25 (Table 4) these represent moderate 
to highly expressed mRNAs. As indicated above with Ct values >30 IGFBP-1 is expressed at 
a very low level and with Ct values typically >35, IGF-I is most likely not expressed by DPCs.  
 
 
 
76 
 
 
 
 
 
 
 
Data are expressed as 2-ΔCt  relative to GAPDH and represent triplicate technical replicates 
of three separated cell cultures (mean ± SD; n=3). Note logarithmic scale of y-axis.  IGF-I 
and IGFBP-1 displayed Ct values > 30 indicating very low expression of these genes. 
 
 
 
 
 
 
 
Figure 11  qRT-PCR analysis of IGF axis expression in DPCs grown under 
basal conditions for 1wk 
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Table 4 A representative set of raw Ct values for IGF axis gene expression in 
DPCs grown under basal conditions indicates reproducibility of data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Also shown are values for the house keeping gene (HKG) GAPDH. Individual triplicate 
values are shown. Note that Ct values vary inversely with mRNA abundance (see Methods 
section). 
 
 
 
 
 
 
 
GAPDH 15.81 17.13 17.71  
IGF-I 35.66 36.46 38.20  
IGF-II 24.41 24.48 25.89  
IGF1R 20.65 22.32 21.65  
IGF2R 20.69 21.74 21.50  
IGFBP-1 31.16 30.63 30.89  
IGFBP-2 20.90 21.27 20.85  
IGFBP-3 23.21 22.96 22.59  
IGFBP-4 15.65 16.64 17.12  
IGFBP-5 18.85 18.89 19.89  
IGFBP-6 20.39 20.56 20.43  
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As this current work is mainly concerned with the osteogenic differentiation of DPCs initially 
we wished to examine how IGF axis expression altered during differentiation. Previous work 
had shown no consistent change in the expression of IGF1R and IGF2R in DPCs following 
differentiation (H. Al-Kharobi PhD Thesis 2016, University of Leeds). Similarly, IGF-I 
expression remained undetectable during osteogenic differentiation of DPCs and we return 
to the issue of IGF-II gene and protein expression later in this thesis (see Section 5.3). For 
the present we focussed on how the expression of IGFBPs was affected by differentiation of 
DPCs.  Fig 11 shows the results of such and experiment where the fold change in IGFBP 
expression is reported using the 2-ΔΔCt method (see 2.2.4.6) and represents the increase 
(>1) or decrease (<1) change in IGFBP expression following incubation of DPCs under 
osteogenic conditions (see Methods). As shown in Fig 12 our data confirm previous 
observations of reciprocal changes in IGFBP-2 and IGFBP-3 expression and we have 
previously reported the potential biological significance of these alterations in IGFBP 
expression [1]. However, of more relevance to the current study we found no significant 
change in the expression of IGFBP-4, -5 or -6 during osteogenic differentiation of DPCs. 
Therefore, our previous studies and this current work have comprehensively detailed the 
changes in IGFBP mRNA expression in DPCs during osteogenic expression. Note that the 
expression of IGFBP-1 remains very low under osteogenic conditions. In order to complete 
our analysis of IGFBP profile in these cells it was important to examine whether the mRNA 
profiles reported above were replicated at the level of IGFBP proteins. As IGFBPs are 
essentially secreted proteins to achieve this we assayed by ELISA the concentrations of 
IGFBP proteins in medium which had been conditioned by DPCs under basal or osteogenic 
conditions. 
 
 
 
79 
 
 
 
 
 
 
IGFBP expression in DPCs grow under basal and osteogenic conditions was analysed using 
the 2-ΔΔCt method (see Methods 2.2.4.6 Data analysis) and represent technical triplicates for 
triplicate cell cultures grown under basal or osteogenic conditions (mean ± SD; n=3). Values 
>1 represent increased expression osteogenic v basal and <1 decreased expression 
osteogenic v basal. IGFBP-1 was expressed at a very low level under both basal and 
osteogenic conditions and is not shown in the Figure (see Fig11 and Table 4). Note 
logarithmic scale for Y-axis. 
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Figure 12 Fold change in IGFBP expression following osteogenic 
differentiation of DPCs for one week. 
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3.3 ELISA of IGFBPs 
 
3.3.1 Assay conditions 
 
Prior to undertaking these experiments, it was important to investigate and establish the 
appropriate conditions for Elisa. For IGFBP-2 and IGFBP-3 these had already been 
established (H Al-Kharobi PhD thesis; University of Leeds 2016) therefore we focussed our 
attention on IGFBP 4-6. Initial experiments for ELISA of IGFBP-4 and IGFBP-5 examined 
the appearance of standard curves for both analytes in a background of different 
buffer/culture media conditions (see Methods 2.2.5.2 for further details). Representative 
results of such an experiment for both IGFBPs are shown in Fig 13. In these experiments 
dilutions of standard were made in buffer containing different ratios of reactant diluent (RD - 
supplied in ELISA kit) and unconditioned serum free medium (M). For IGFBP-4 
concentrations of standard were diluted 2-fold between 0.5-32 ng/ml and for IGFBP-5 
standards were diluted 2-fold between 0.625-40 ng/ml. For both IGFBP-4 and IGFBP-5 
assay interference was apparent as the ratio RD: M increased. In practice this meant that 
assays of cell conditioned medium were conducted in samples which were diluted at least 
1:10 in RD. At this level of dilution concentration values for both IGFBP-4 and IGFBP-5 fell 
within the standard curve which was also constructed using standards which were diluted in 
a 1:10 (RD:M) buffer background. It is important to note that failure to perform such 
preliminary experiments would lead to an underestimation of IGFBP-4 and -5 levels if 
inappropriately large volumes of cell conditioned medium were assayed. Fortunately for 
IGFBP-6 no issues of assay interference were evident although in interests of consistency 
IGFBP-6 ELISA and standard curves were also performed at 1:10 (RD:M) dilutions and 
under these conditions IGFBP-6 concentrations also fell within the assay range. After 
establishing these assay conditions, we then assayed DPC conditioned medium for IGFBP 
content.  
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 Standard curves for IGFBP-4 (0-32 ng/ml) and IGFBP-5 (0-40 ng/ml) were constructed in 
varying ratios of reactant diluent (RD) to culture medium (M) as indicated. Standards were 
assayed as duplicates although for clarity only mean values are shown. Increasing RD: M 
ratios led to increased interference for both IGFBP-4 and IGFBP-5 ELISA. 
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Figure 13 Culture medium interferes with assay of IGFBP-4 and IGFBP-5 
present in conditioned medium 
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3.3.2 IGFBP concentration in conditioned medium 
 
Using the conditions established above for IGFBP4-6 and those previously described for 
IGFBP-2 and IGFBP-3 (H.Al-Kharobi, PhD Thesis; University of Leeds 2016) we assayed 
IGFBP concentrations in DPC conditioned medium under both basal and osteogenic 
conditions (Fig 14). We confirm previous observations of reciprocal alterations in IGFBP-2 
and IGFBP-3 protein concentrations following osteogenic differentiation of DPCs. However, 
we show that for IGFBP-4, -5 and -6 there is no change in protein concentrations in 
conditioned medium following differentiation of DPCs. We would also highlight that the 
relative IGFBP protein abundance closely mirrors that for IGFBP mRNA expression 
(compare Fig 11 and Fig 14). In accordance with this IGFBP-4 (~ 80 ng/ml) is more 
abundant than the combined concentrations of IGFBP-5 (~12ng/ml), IGFBP-6 (~3 ng/ml), 
IGFBP-2 (~2 ng/ml) and IGFBP-3 (~0.25 ng/ml). Therefore, although we have previously 
reported on the effects of IGFBP-2 and IGFBP-3 as an enhancer and inhibitor respectively of 
IGF-I action in DPCs the fact that IGFBP-4 and IGFBP-5 are more abundantly expressed in 
these cells led us to investigate the potential biological activity of these IGFBPs in our DPC 
cultures. Prior to this we wished to confirm independently in our hands that IGFs were 
biologically active in DPC cultures. 
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conditioned medium in cells grown under basal or osteogenic conditions. Data are derived 
from triplicate technical replicate assays of conditioned medium derived from 3 separate cell 
cultures grown under basal or osteogenic conditions and represent mean ± SD (n=3). Based 
on qRT-PCR data IGFBP-1 ELISA was not performed. * p< 0.05 Student’s t-test basal v 
osteogenic. Note split Y-axis scale. 
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Figure 14 Elisa determination of IGFBP-2, 3, 4, 5 and 6 protein concentrations in 
DPC 
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3.4 IGF activity in DPCs 
As indicated above the biological end point for most of our studies was the differentiation of 
DPCs into matrix secreting osteoblast like cells. Amongst assays used to measure the 
differentiation of mesenchymal cells into pre-osteoblast or osteoblast cells are colorimetric 
detection of matrix in cells culture (usually Alizarin Red ) [256] and /or detection of 
osteogenic specific markers such as RunX2, Osteocalcin (OCN) or alkaline phosphatase 
(ALP) and our group has routinely used such assays to monitor osteogenic differentiation of 
DPCs [257]. ALP in particular lends itself to a moderately high throughput assay in that ALP 
enzyme activity is easily measured in cell lysates following exposure of intact cell cultures to 
various osteogenic conditions [258, 259].  Initially therefore we examined both Alizarin Red 
and alkaline phosphatase activity in DPCs under basal and osteogenic conditions and the 
effect of IGF-I at a single concentration of 100nM under both these conditions. The results of 
this experiment are shown in Fig 15. For Alizarin Red based assay addition of 100 nM IGF-I 
increased staining in cultures under both basal and osteogenic conditions. It is believed that 
even in the absence of osteogenic agents a proportion of MSCs in confluent cultures may be 
able to partially differentiate. In our hands only low levels of Alizarin Red staining was 
apparent under basal conditions although this was stimulated by addition of IGF-I (Fig 15 - 
first two columns upper panel). Under osteogenic conditions Alizarin Red staining was 
clearly increased (compare columns 3 and 1) and this effect was further enhanced under 
osteogenic conditions in the presence of IGF-I (compare columns 3 and 4). Very similar data 
were seen when ALP activity was measured in DPC cells treated under conditions identical 
to those for Alizarin Red assay with IGF-I enhancing ALP enzyme activity under osteogenic 
conditions. Because the ALP assay appeared to provide a greater signal to noise ratio in 
terms of the IGF-I enhancement of osteogenic activity and also due to the fact that ALP 
assay lends itself to a higher throughput of samples we decided to concentrate on 
developing this assay in our future studies. The ALP assay described in Fig 15 was 
conducted over a 14 day incubation period. However, in order to examine the time course of 
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IGF-I stimulation of ALP activity we carried out the experiment described in Fig 16. This 
experiment showed that a significant stimulation of osteogenesis in the absence of IGF-I 
occurred at day 14 of incubation. However, in the presence of 100nM IGF-I a significant 
stimulation of osteogenesis was evident at day 10 of incubation. Although this significant 
effect of IGF-I persisted at days 14, 17 and 21 of incubation the greatest effect of IGF-I in the 
presence of osteogenic medium versus osteogenic medium alone (i.e. O v O+IGF-I) was 
apparent at day 10. Therefore, as this was also the earliest time point at which significant 
differences were seen (O v O+IGF-I) we used this incubation time point in subsequent 
studies. After these preliminary experiments we then went on to examine the effects of the 
two most abundantly expressed IGFBPs – IGFBP-4 and IGFBP-5 – on the action of IGF-I 
(and independently of IGF-I) in DPCs.  
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 Semi-quantitative assay for Alizarin Red staining (upper panel) and alkaline phosphatase 
activity (lower panel) in DPCs grown under basal (B) or osteogenic (O) conditions in the 
absence (-) or presence (+) of 100 nM IGF-I for 14 days. Data are derived from triplicate 
cultures assayed as technical duplicates and are presented as mean ± SD (n=3). *p<0.05, 
**p< 0.01. See Methods section 2.2.6 for further details. 
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Figure 15 Semi-quantitative assay for Alizarin Red staining and Alkaline 
phosphatase activity 
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DPCs were grown under basal or osteogenic conditions as indicated in the presence or 
absence of 100 nM IGF-I. Cultures were terminated on days 4, 7, 10, 13, 17 and 21 and 
assayed for AP activity. Assays were performed in triplicate and are presented as mean ± 
SD (n=3). In some instances, SD values are lower than symbol size. * p<0.05 O+IGF-I v 
IGF-I. This experiment was performed twice with similar results in each instance. 
 
 
 
Figure 16 Time course for AP activity in DPCs grown over the period 0-21 days 
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3.5 Activity of IGFBP-4 and IGFBP-5 in DPCs 
In order to examine the effect of IGFBP-4 and IGFBP-5 in DPCs we conducted the 
experiments described in Fig 17. In this experiment we conducted a dose-response 
experiment over the range of 0-100 nM IGF-I in the presence of a fixed concentration (10 
nM) of IGFBPs using ALP activity as an end point of biological activity. As indicated in the 
data below both IGFBP-4 and IGFBP-5 inhibited the activity of IGF-I over the concentration 
range of IGF-I which was used. It is important to note that at a concentration of 10nM, 
IGFBP is present at a ratio of equimolar, sub-equimolar and supra-equimolar with respect to 
IGF-I (1, 10 and 100). It is also important to note that this experiment involved the addition of 
exogenous IGFBP-5 and IGFBP-4 together with exogenous IGF-I after a 30 min pre- 
incubation period. Note also that in the presence of IGFBP-4 or IGFBP-5 alone (zero IGF-I 
Fig 17) there is no effect on ALP activity. We discuss both of these features below (Section 
3.3.5). 
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Cells were incubated for 10 days in the presence of varying concentrations (0-100 nM) of 
IGF-I in the presence of a fixed concentration (10 nM) of IGFBP-4 or IGFBP-5. Data are 
derived from triplicate cultures of DPCs each assayed in technical triplicates and are 
presented as mean ± SD (n=3). * p< 0.05 IGF-I v IGF-I+IGFBP-4/5. Note that in the absence 
of IGF-I (0 nM) neither IGFBP-4 nor IGFBP-5 showed any effect on AP activity. 
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Figure 17 Effect of inhibitory action IGFBP-4 and IGFBP-5 on IGF-I in DPC 
grown under osteogenic conditions 
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3.6 Discussion 
We have quantified IGFBP mRNA and protein expression in DPCs and shown that with the 
exception of IGFBP-1 DPCs express each of the well characterised high affinity IGFBPs. 
IGFBP-4 is the most abundant IGFBP expressed under both basal and osteogenic 
conditions. Surprisingly very few studies have reported quantitative data for all IGFBP 
species expressed in a given cell culture system. This is rather surprising given that a 
complete picture of IGFBP profile (qualitative and quantitative) is required for the 
interpretation of both IGF-dependent and IGF-independent effects of IGFBPs. In general 
terms IGFBPs are thought to be expressed at higher concentrations than IGFs in osteoblast 
and fibroblast cultures [203]. This is the case in our DPC cultures under both basal and 
osteogenic conditions where global IGFBP concentration is approximately 4 nM and IGF-II is 
present at 0.1nM (see Appendix Table II and Chapter 5). Therefore, under basal conditions 
this represents an IGFBP: IGF ratio of 40 and suggests that the majority of IGF-II in DPC CM 
is bound to IGFBPs. Later in this thesis we also show the IGF-II protein concentration in 
osteogenic conditioned medium is higher than under basal conditions. We return to this topic 
later in this thesis.  Although we did not detect IGF-I mRNA or protein in DPC cultures, 
exogenous IGF-I was shown to stimulate osteogenic differentiation of DPCs (Figs 15-17) 
confirming reports from previous groups [223, 224]. In this regard it is important to note that 
dental pulp is a well vascularised tissue and IGF-I therefore may access DPCs through the 
systemic circulation or via paracrine expression in neighbouring cells. Our finding of higher 
expression of IGF-II than IGF-I in DPCs has also been reported previously in osteoblast 
cultures [102, 260] and in DPCs [238]. 
 We have recently shown that IGFBP-2 enhanced and IGFBP-3 inhibited the pro-osteogenic 
effects of IGF-I in DPCs. This was co-ordinated with increased and decreased expression of 
IGFBP-2 and IGFBP-3, respectively, during differentiation of these cells [1]. The expression 
of IGFBP-4 and IGFBP-5 did not change during DPC differentiation (Figs 12 and 14), but as 
these IGFBPs are 10-100 fold more abundant than IGFBP-2 or IGFBP-3 (Figs 11 and 14), 
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we investigated the effect of IGFBP-4 and IGFBP-5 on the osteogenic activity of IGF-I. Fig 
17 shows that both IGFBPs at equimolar concentrations inhibit the pro-osteogenic action of 
growth factor. For IGFBP-4, this inhibitory effect is in agreement with most in vitro studies in 
cultured osteoblasts [121, 149]. For IGFBP-5, both inhibitory [127-130] and stimulatory [117-
119, 123]  effects on osteoblast activity have been described. We found no evidence of 
enhancement of IGF-I activity by exogenous IGFBP-5 added to DPC cultures. In addition, 
neither IGFBP-4 nor IGFBP-5 stimulated ALP-activity independently of IGF-I. Interestingly 
the inhibitory effect of IGFBP-4 and -5 was not overcome by increasing concentrations of 
IGF-I. Although we have no ready explanation for this, we would emphasise that the affinity 
of IGFBPs for IGFs is 10-fold higher that of IGF1R and it may be that IGFBP-4 and-5 can 
concentrate IGFs within the abundant extracellular matrix secreted by DPCs. Investigations 
into this phenomenon are continuing in our laboratory. It is also the case that the activity of 
IGFBP-4 and IGFBP-5 can be modified by proteolysis in cell culture. In the next Chapter we 
examine this phenomenon in DPC cultures. 
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Chapter 4 IGFBP proteolysis in DPC 
 
4.1 Introduction 
Although we have shown that IGFBP-4 and IGFBP-5 mRNA and protein levels did not 
change during osteogenic differentiation of DPCs (Chapter 3) as indicated above we wished 
to test the hypothesis that IGFBP-4 and IGFBP-5 proteolysis may be differentially regulated 
between basal and osteogenic conditions. 
4.2 Western blot (WB) analysis of endogenous IGFBP-4 and IGFBP-5 
proteolysis 
 In order to examine this possibility, we conducted Western blotting experiments of medium 
conditioned under basal and osteogenic conditions by DPC cultures. In Fig 18 we show the 
results of a representative blot from this series of experiments. For IGFBP-4 (left panel Fig 
18) the intact protein runs in SDS-PAGE with a molecular weight (Mr) of 28 kDa. It is evident 
that there is extensive proteolysis of IGFBP-4 under both basal and osteogenic conditions to 
produce two distinct fragments of approximate Mr of 18 and 14 kDa. At this stage we would 
draw attention to the fact that at the 24hr incubation point intact IGFBP-4 has almost 
disappeared from the osteogenic conditioned medium. In the basal conditioned medium at 
24hr incubation some intact IGFBP-4 is still present. However, at the 48hr time point very 
little intact IGFBP-4 is evident. For IGFBP-5 (right panel Fig18) the intact protein runs in 
SDS-PAGE with an Mr of 32 kDa. Under all conditions osteogenic + basal, 24 and 48 hr 
incubations very little intact IGFBP-5 is apparent. However, unlike IGFBP-4, for IGFBP-5 a 
broad band of reactivity is apparent between the15 and 20 kDa Mr markers. This implies that 
whereas IGFBP-4 appears to be proteolysed at a discrete site within the protein, IGFBP-5 
may be a substrate for several different proteases.  
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Western blot analysis of endogenous IGFBP-4 (left panel) and IGFBP-5 (right panel) in DPC 
medium conditioned under basal (B) or osteogenic (O) conditions for 24 or 48hr. The 
expected locations for intact IGFBP-4 (28kDa) and the presence of 18 and 14 kDa IGFBP-4 
fragments is indicated (left panel). Similarly, the expected location of intact IGFBP-5 (32kDa) 
along with a broad smear of reactive IGFBP-5 fragments is also indicated (right panel). This 
experiment was repeated with different batches of DPCs on at least 5 occasions and similar 
results were obtained in each instance. A representative blot is shown. 
 
 
 
 
Figure 18 Western blot analysis of endogenous IGFBP-4 and IGFBP-5 
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Given the appearance of intact IGFBP-4 under basal but not osteogenic conditions, we 
decided to explore further the potential differential proteolysis of IGFBP-4 under basal or 
osteogenic conditions. Therefore, we performed several WBs for endogenous IGFBP-4 in 
medium conditioned by DPCs under basal and osteogenic conditions. A representative of 
such a blot is shown in Fig 19 upper panel. It is clear from this data that IGFBP-4 is 
proteolysed to a greater extent under osteogenic conditions compared to basal conditions. 
This is confirmed by densitometric analysis of such data which indicates that 82.7±3.3% 
remains intact under basal conditions while in osteogenic cultures 38.2±5.4% of IGFBP-4 
remains intact. We discuss the potential implications of these findings below. 
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Cells were treated under basal (B) or osteogenic (O) conditions for 7 days. CM was 
subsequently collected over a 24hr time period, freeze dried, reconstituted at x5 
concentration in dH2O then stored at -80C prior to analysis.  Location of intact (I) and 
fragmented (f) IGFBP-4 are indicated (arrows). Triplicate lanes were run for both basal and 
osteogenic CM. The central two lanes contain unconditioned medium controls. This 
experiment was repeated on 5 occasions with similar results in each instance. Bottom panel 
densitometric analysis of %intact protein * p< 0.05 basal v osteogenic mean ± SD (n=3). 
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Figure 19 WB analysis of endogenous IGFBP-4 profile 
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4.3 PAPP-A activity in DPCs 
As indicated above PAPP-A is reported to cleave IGFBP-4 into two discrete fragments 
similar to those we report above for DPCs. In order investigate whether PAPP-A was 
involved in IGFBP-4 proteolysis in DPC conditioned medium we conducted the experiment 
described in Fig 20 in collaboration with Dr Claus Oxvig at the University of Aarhus, 
Denmark. These in vitro experiments use 125I-labelled IGFBP-4 as a substrate for PAPP-A.  
Under these assay conditions recombinant PAPP-A proteolyses radio-labelled IGFBP-4 into 
a lower Mr species (lane 2 Fig 20). In the presence of an inhibitory PAPP-A antibody (1/41) 
this proteolysis is inhibited whereas incubation with a control IgG antibody has no effect 
(compare lanes 3 and 4 Fig 20). Importantly medium conditioned by DPCs under basal (B) 
or osteogenic (O) conditions displays a proteolytic activity towards 125I-IGFBP-4 and this 
activity can be completely inhibited by the anti-PAPP-A antibody 1/41 (lanes 5-8 Fig 20). 
Again, importantly this suggests that all of the IGFBP-4 proteolytic activity in DPC 
conditioned medium is represented by PAPP-A 
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125I-IGFBP-4 was incubated under cell free conditions with the following additions: Lane 1 
control; lane 2 rPAPP-A only; lane 3 = rPAPP-A + inhibitory antibody (1/41 - PA Ab); lane 4 
= rPAPP-A + control Ab; lane 5 = basal CM + control Ab; lane 6 = basal CM + inhibitory 
antibody; lane 7 = osteogenic CM + control Ab; lane 8 = osteogenic CM + inhibitory 
antibody. Incubations were conducted over 6 hours period. The location of intact (i) and 
cleaved (f) IGFBP-4 is indicated. See Methods 2.2.7 for further details. 
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Figure 20 Identification of IGFBP-4 proteolytic activity in DPC CM 
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4.4 Discussion 
Although we show that IGFBP-4 concentrations are not altered following osteogenic 
differentiation of DPCs, it is well established that the activity of IGFBP-4 in fibroblast and 
osteoblast cultures can be modified by IGF-dependent proteolysis [166, 168]. We therefore 
examined whether there was any difference in IGFBP-4 proteolysis between basal and 
osteogenic DPC cultures. To investigate proteolysis of endogenous IGFBP-4, we conducted 
WB analysis of DPC CM. We found that IGFBP-4 was proteolysed into fragments which 
migrated at 18 and 14 kDa in reducing SDS-PAGE (Fig 18). This is similar to previously 
described endogenous IGFBP-4 proteolysis in osteoblast cultures [167]. However, in 
medium conditioned for 24hr under basal conditions, we repeatedly observed that a higher 
proportion of intact IGFBP-4 was present compared to CM from osteogenic cultures (Fig18). 
As IGFBP-4 protein concentrations are equivalent by ELISA between basal and osteogenic 
media (Fig 14 and Appendix Table II), this suggests increased IGFBP-4 proteolysis under 
osteogenic conditions (note that the IGFBP-4 ELISA detects both intact and fragmented 
IGFBP-4 species. Repeated Western blot experiments confirmed an increased proteolysis of 
IGFBP-4 under osteogenic conditions (Fig 19). PAPP-A has been characterised as an 
IGFBP-4 protease expressed by several cell types (reviewed in [261]) and our experiments 
in cell free assays suggested that most, if not all IGFBP-4 proteolysis was due to the activity 
of PAPP-A present in CM (Fig 20) and that the difference between co-migration of IGFBP-4 
fragments in cell free assay (Fig 20) compared with the resolvable IGFBP-4 fragments 
evident during endogenous IGFBP-4 proteolysis (Fig 19) is explained by the use of a tagged 
recombinant IGFBP-4 species for cell free assay. Note that in (Fig 20) there is less 
difference in intensity between IGFBP-4 fragments in the basal and osteogenic media (lanes 
5 and 7) treated cultures than that seen in the tissue culture experiments described in (Fig 
18). Note however, that the invitro assays described in (Fig 20) were conducted over a 6 
hour time course as opposed to 24 and 48 hour incubation periods for the tissue culture 
experiments described in (Fig 18). therefore, the shorter time period used for the invitro 
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proteolysis experiments may not allow so obvious differences in IGFBP-4 proteolysis to be 
apparent. We also performed WBs for endogenous IGFBP-5 in DPC CM. In this instance, 
we found that little intact 32 kDa IGFBP-5 was present in either basal or osteogenic DPC CM 
with most protein running as a broad band between 15-20 KDa. This may represent the 
proteolysis of IGFBP-5 by several proteinases known to act on this IGFBP each with 
different cleavage sites [131, 132]. Time pressure precluded further analysis of IGFBP-5 
proteolysis in this experimental model. Furthermore, IGFBP-2 is also known to be 
proteolyzed by PAPP-A and is expressed by DPCs. Again, pressure of time precluded 
further studies of IGFBP-2 proteolysis. 
At this stage of our studies we began to formulate the idea of an “integrated IGF axis 
signature” associated with the pro-osteogenic activity of the IGF axis in DPCs. In this model 
the inhibitory action displayed by IGFBP-4 (Fig17), the most abundant IGFBP in DPC cells 
(Fig14) is attenuated by increased proteolysis of this IGFBP (Fig19) to a non-IGF binding 
species thus allowing the osteogenic activity of IGFs (Fig15-17) to act in DPC cells in 
culture. We investigate this phenomenon further in the next Chapter where we provide 
additional evidence for the existence of this novel signature of IGF axis expression and 
activity during osteogenic differentiation of DPCs.  
 
 
 
 
 
100 
 
 
Chapter 5 An IGF axis signature in differentiating DPCs 
5.1 Introduction 
In the previous section we suggested that a characteristic signature of IGF axis expression 
and activity may be associated with osteogenic differentiation of DPCs. In the Introduction 
section Sections 1.3- 1.5 we discussed the importance of the IGF axis in bone physiology, 
introduced some of the literature describing how IGFBP-4 (1.4.4) and PAPP-A (1.5) may 
play a role in this process. In the previous Chapter we showed that increased IGFBP-4 
proteolysis occurs in DPCs during osteogenic differentiation and that proteolysis is catalysed 
by PAPP-A. To further characterise this process, we first of all examined directly PAPP-A 
expression in DPC cultures. 
 5.2 PAPP-A expression in DPCs 
ELISA for PAPP-A protein (upper panel Fig 21) indicated increased concentrations of 
enzyme under osteogenic culture conditions compared to basal culture conditions. In both 
1wk and 3wk cultures in which serum free medium was conditioned for a 24hr period PAPP-
A concentrations were approximately 2-fold higher in osteogenic cultures (18.7 ± 1.0 v 37.6 
± 2.2ng/ml – 1wk cultures and 17.7 ± 1.0 v 29.2 ± 4.4 ng/ml 3 wk cultures). Within each 
condition – basal or osteogenic - there was little difference in PAPP-A concentrations within 
the 24hr conditioning period irrespective of whether 24 hr conditioned medium was collected 
after 1wk or 3wk of culture. This suggests a consistent rate of PAPP-A protein expression 
over this period with maintenance of increased concentrations in differentiated cultures. This 
evidence of increased PAPP-A enzyme protein in osteogenic DPC cultures is consistent with 
the increased levels of IGFBP-4 proteolysis seen differentiating DPC cultures. However, 
examination of PAPP-A mRNA expression under the same conditions showed no significant 
differences between basal and osteogenic cultures at either 1 or 3 wk time point (bottom 
panel – Fig 21). We discuss this finding at length in Section 5.7   
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DPC were treated under basal or osteogenic conditions for 1 or 3wk. Following this 
medium was conditioned over a 24hr time period and retained for PAPP-A ELISA. 
mRNA was prepared from the same cell cultures and PAPP-A mRNA levels were 
determined by qRT-PCR. Data are derived from triplicate cultures with duplicate 
technical replicates and are expressed as mean ± SD (n=3). * p<0.05; p< 0.005. ELISA 
data are expressed as ng/ml and qRT-PCR data are expressed relative to GAPDH. 
Triplicate technical replicates were formed on 3 separate cell preparations. Data are 
expressed as mean±SD (n=3). * p<0.05; ***p<0.005. 
Figure 21 PAPP-A protein (upper panel) and mRNA (lower panel) expression 
in DPC were determined by ELISA and qRT-PCR respectively 
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5.3 IGF2 expression in DPCs 
As indicated in the Introduction of this thesis the proteolysis of IGFBP-4 by PAPP-A requires 
the obligatory presence of IGF. Data generated in the early part of our research indicated 
that IGF-I was only expressed at a very low level by DPCs (see Fig11 and Table 4). 
However, these experiments did indicate that IGF-II mRNA was expressed in DPCs. 
Therefore, we decided to revisit this area and determine whether IGF-II protein was present 
in DPC conditioned medium. Fig 22 clearly shows that IGF-II protein is detectable in DPC 
conditioned medium and confirms our qRT-PCR data. However perhaps of more 
significance IGF-II concentrations are increased almost 10-fold under osteogenic conditions 
6.4 ± 0.28 v 0.69 ± 0.17ng/ml. This also confirms previous data with respect to increased 
IGF-II mRNA expression in osteogenic DPCs (H Al-Kharobi 2016 PhD Thesis University of 
Leeds – unpublished observations). In addition, we have previously shown that IGF-II 
stimulates osteogenic differentiation of DPCs [1]. Therefore, the presence of IGF-II protein in 
DPC cultures may have significant implications and we discuss these further in Section 5.7. 
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IGF-II was assayed by ELISA under both basal and osteogenic conditions in DPC 
cultures grown for 1wk under basal or osteogenic conditions. Medium was conditioned 
for a period of 24hr after culture. Conditioned medium from triplicate cultures was 
assayed as technical triplicates and data is expressed as ng/ml mean ± SD (n=3). * 
p<0.0001 
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Figure 22 IGF-II protein expression in DPCs 
104 
 
 
5.4 Stanniocalcin (STCs) mRNA expression in DPCs 
Stanniocalcins (STCs) are recently described inhibitors of PAPP-A activity (see Introduction 
P43). There are two STC proteins (STC-1 and STC-2) which have been identified in 
mammalian species. However, to date there are very little data on the cellular expression of 
either of these proteins. To investigate whether STCs are expressed in DPCs and whether 
they are able to regulate PAPP-A activity (and therefore indirectly regulateIGFBP-4 
proteolysis) we initially investigated both STC1 and STC2 expression in DPCs. We found 
that STC2 was the more abundant isoform expressed in DPCs (Fig 23 – note logarithmic Y-
axis). However, although there was a statistically significant increase in STC1 expression 
under osteogenic conditions in DPC cultures we found no difference in STC2 mRNA levels 
between basal and osteogenic cultures (but see Fig 23 below). This figure also confirms 
equivalent PAPP-A expression in basal and osteogenic DPC cultures (see also Fig21-lower 
panel). As STC2 was expressed at an almost 100-fold greater level than STC1 in DPC 
cultures we decided to focus on STC2 expression and activity in DPCs.  
5.5 STC2 protein expression in DPCs 
ELISA of DPC conditioned medium indicated that STC2 protein was present (Fig 24). 
Furthermore, the concentration of STC2 was reduced over 5-fold in in osteogenic v basally 
conditioned medium 0.77±0.64 v 4.3±1.8 ng/ml. As STC2 is reported to be an inhibitor of 
PAPP-A (see Section 1.5.3) these reductions in STC2 protein concentrations are consistent 
with increased PAPP-A activity in osteogenically conditioned medium. However, note that 
there is an apparent disconnect between STC2 mRNA and protein levels (Fig 23 and 24) 
with no change in STC2 mRNA levels despite decreased STC2 protein in osteogenic DPC 
conditioned medium. We return to this topic below. STC2 forms covalent disulphide bonded 
complexes with PAPP-A and in this complex PAPP-A activity is inhibited (Section 1.5.3). 
Therefore, in the next series of experiments we decided to investigate whether PAPP-
A/STC2 complexes could be formed in DPC conditioned medium. 
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Data are expressed relative to GAPDH and represents technical triplicate replicate 
assays on three different preparations of DPCs grown for 1wk under basal or osteogenic 
conditions. Mean±SD n=3. * p< 0.05 basal v osteogenic. 
 
 
 
 
 
 
 
Figure 23 qRT-PCR analysis of STC expression in DPCs 
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DPCs were treated under basal or osteogenic conditions for 7 days and serum free CM was 
subsequently collected over a 24hr time period. Assays were performed as technical 
triplicates of 3 separate preparations of CM and are presented as ng/ml mean±SD (n=3); * 
p< 0.01  
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Figure 24 Stanniocalcin-2 (STC2) concentrations in basal or osteogenic CM 
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5.6 PAPP-A: STC2 complexes in DPC conditioned medium 
To investigate whether endogenous PAPP-A in hDPC CM can complex with STC2, we 
carried out the series of experiments described in Figs 25-27.  In Fig25 immuno-
precipitation (IP) of DPC CM with anti-PAPP-A: protein G Sepharose followed by Western 
blotting (WB) with a separate PAPP-A antibody indicated the presence of a high molecular 
weight doublet. This reactive doublet was evident following IP/WB of both basal (lanes 4, 5, 
7, 8) and osteogenic (lanes6, 9) medium. The lower molecular weight species most likely 
represents the PAPP-A homodimer which runs at approximately 400kDa under the non-
reducing conditions used in these experiments (see also [204]). Although unidentified by this 
experiment the slower migrating species (~500 kDa) may represent covalent disulphide 
linked PAPP-A: STC2 complexes (see Section 1.5.3 and [204]). Note that in experiments 
conducted on DPC CM collected from cultures after both 1wk (lanes 4-6) and 3wk (lanes 7-
9) there was evidence of increased intensity of the lower molecular weight species in 
osteogenic v basal DPC CM (compare lane 6 v 4 and 5 in basal IP reactions and lane 9 v 7 
and 8  in osteogenic  IP reactions. The presence of increased uncomplexed PAPP-A under 
osteogenic conditions is again consistent with increased PAPP-A activity and IGFBP-4 
proteolysis in osteogenic conditions. This also most likely reflects the different PAPP-A and 
STC2 concentrations in basal and osteogenic CM (see Figs 21 and 24). Also note the 
apparent increased reactivity for all species in 3wk v 1wk cultures (compare lanes 7-9 v 4-6 
in Fig 25).  
Although these initial experiments suggested that PAPP-A: STC2 complexes may exist in 
DPC CM, further evidence for this conclusion was required. Fig 26 shows the results of an 
experiment similar to that described in Fig 25. In this instance IP of PAPP-A from CM was 
performed in the absence or presence of added rSTC2. It is clear that in those IP reactions 
which contained added STC2, there was a decrease in intensity of the faster migrating 
uncomplexed PAPP-A species and an increase in the intensity of the more slowly migrating 
PAPP-A: STC2 complex. This was particularly evident in CM from DPCs grown under basal 
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conditions (lanes 2-4 Fig 26). Although this data provided further evidence for the formation 
of PAPP-A: STC2 complexes in DPC CM and through this the potential regulation of PAPP-
A activity, we conducted one final experiment in this series to try and obtain further 
confirmation of the existence of such complexes in DPC CM.  
 Finally, to confirm the presence of STC2 in complexes from hDPC CM, the experiments 
described in Fig 27 were conducted.  IP by anti-STC2: protein G Sepharose complex 
followed by non-reducing WB of STC2 in both basal (lanes 1 and 2) and osteogenic (lane 3) 
CM show STC2 present as a high Mr complex (>500 kDa) as well as free STC2 dimer and 
monomer migrating at 90 and 45 kDa respectively. Although the data for the basal CM is 
variable (lanes 1 and 2) there is evidence that in osteogenic CM there is less free STC2 
present as the 70 kDa dimer (compare lane 3). This data is consistent with lower 
concentrations of STC2 in osteogenic compared to basal CM (Fig 24). Taken as a whole the 
data in Figs 25-27 suggest that in hDPC cells PAPP-A activity may be regulated by 
formation of PAPP-A: STC2 complexes.  
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Basal (lanes 4,5,7 and 8) or osteogenic (lanes 6 and 9) CM collected over a 24hr time period from cultures grown for 1wk (lanes 4-6) or 3wk 
(lanes 7-9). Uncomplexed PAPP-A runs at 400 kDa (lower red arrow) and slower migrating putative PAPP-A: STC2 complexes (upper red 
arrow) run above this. Negative controls- lane 1 PBS; lanes 2 no IP; lane 3 no IP with rPAPP-A+rSTC2. Positive controls- lane 10 IP with 
rPAPP-A+rSTC2 (upper black arrow); lane 11 IP with rPAPP-A alone (lower black arrow). WBs were run under non-reducing conditions. See 
2.2.8 Methods for further details 
Figure 25 IP/WB detection of PAPP-A species in DPC CM 
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Basal (lanes 2-4) and osteogenic (lanes 5-7) DPC CM was collected from cultures grown for 1wk. PAPP-A IP and subsequent WB was 
performed in the absence (lanes 2,3,5,6) or presence (lanes 4 and 7) of added rSTC2. Note decreased intensity of lower molecular weight 
species in the presence of added rSTC2. Negative controls lane 8-rPAPP-A only; lane 9 no IP. Positive controls lanes 10-12 show the time 
dependent association of PAPP-A and STC2. Lower red arrow uncomplexed PAPP-A; upper red arrow PAPP-A: STC2 complexes. 
Figure 26  IP/WB analysis of PAPP-A: STC2 complexes in DPC CM. 
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Basal (lanes 1 and 2) or osteogenic (lane 3) CM were immunoprecipitated with anti-STC2: protein G Sepharose followed by WB with a 
different STC2 antibody. Indicated are the locations of STC2 monomer (35 kDa), dimer (70 kDa) and putative PAPP-A: STC2 complexes 
(500kDa). Lane 4 STC2 +ve control; lane 5 PAPP-A –ve control. Note that the central portion of this blot has been removed. 
Figure 27 IP/WB of STC2 in DPC CM 
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5.7 Discussion 
In the previous chapter we suggested the idea of an IGF axis signature associated with the 
osteogenic differentiation of DPCs- see Section 4.4. In this Chapter we investigated this hypothesis 
further. Although we previously demonstrated increased IGFBP-4 proteolysis in osteogenic CM (Fig 
19) and provided strong evidence that PAPP-A was the only IGFBP-4 protease present in DPC CM 
(Fig 20) to examine the hypothesis of increased PAPP-A activity in osteogenic medium more 
directly, we assayed PAPP-A protein levels in basal and osteogenic CM by ELISA (Fig 21). This 
indicated increased PAPP-A protein in osteogenic medium vs. basal medium in both 1wk and 3wk 
cultures. In 1 wk cultures PAPP-A concentrations were increased approximately 2-fold basal vs. 
osteogenic and these differences in PAPP-A protein concentrations are also evident in 3wk DPC 
cultures. These findings are consistent with a pattern of gene expression and/or activity which 
promotes IGF activity during osteogenic differentiation of DPCs. It is also worth comment that these 
concentrations of PAPP-A represent a rather high endogenous enzyme-to-substrate ratios (between 
1:2 and 1:10) and may partly explain the extensive proteolysis of endogenous IGFBP-4 evident 
under both basal and osteogenic conditions. Also worthy of note in our experiments, no difference 
was apparent in PAPP-A mRNA expression between basal and osteogenic DPC cultures in either 
1wk or 3wk cultures (Fig 21 – bottom panel). This suggests that increased PAPP-A protein 
concentration in osteogenic CM is the result of post-transcriptional or post-translational 
mechanisms. Although we have no ready explanation for this at present, PAPP-A is known to 
associate with cell membranes [176] and we are investigating the possibility that increased release 
of membrane associated PAPP-A protein may occur under osteogenic conditions. Alternatively, 
PAPP-A ELISA may be affected by the presence of increased PAPP-A: STC2 complexes in basal 
CM which may not be detected by the PAPP-A ELISA. However, we provide some evidence via 
IP/WB experiments for increased PAPP-A protein in osteogenic CM (Fig 26) and although these 
issues may be worthy of further investigation this would not alter the conclusion of increased 
IGFBP-4 proteolysis under osteogenic conditions.  
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We demonstrate a dislocation between gene transcription and protein expression at several 
locations in this thesis. There may be several reasons for this. It is well known that abundance of 
protein target is not solely a function of corresponding mRNA abundance. Many factors including 
microRNA (miRNA) and non-coding RNA (ncRNA) can potentially regulate protein translation [262, 
263]. Whether any of these factors operate in our experimental model is worthy of further 
investigation. 
 As PAPP-A proteolysis of IGFBP-4 is IGF dependent, this suggests that IGFs are present 
endogenously in DPC CM and actually bound to this IGFBP. We confirmed the expression of 
IGF-II in DPC cultures (Fig 22) and that IGF-II is active in DPCs most probably through the 
IGF1R (Fig 5). Indeed IGF-II is a more potent activator of IGFBP-4 proteolysis than IGF-I 
[181] and  significantly the concentration of IGF-II was approximately 10-fold higher in 
osteogenic vs. basal medium (Fig 22 and Appendix  Table II). This increased IGF-II 
concentration under osteogenic conditions would be expected to increase the fraction of 
IGFBPs (including IGFBP-4) associated with IGF-II. This would in turn increase substrate 
availability (IGFBP-4: IGF-II complexes) for PAPP-A and may contribute towards increased 
proteolysis of IGFBP-4 under osteogenic conditions. Importantly increased local IGFBP 
proteolysis may enhance the action of systemically derived IGF-I which reaches dental pulp 
tissue. In this instance therefore IGF-II and IGF-I are seen to act in concert to promote cell 
differentiation. 
 Recently, PAPP-A activity was shown to be inhibited by both STC1 and STC2 [204, 205]. 
To determine whether PAPP-A activity may be regulated by either of the STCs, we initially 
examined the expression of STC1 and STC2 using qRT-PCR. We found that STC2 mRNA 
was over 100-fold more abundant than STC1 in DPC cultures (Fig 23). Further to this, 
ELISA of CM indicated that STC2 levels in osteogenic medium were almost 6-fold lower than 
those in basal medium (Fig 24). This lower concentration of inhibitory STC2 in osteogenic 
compared to basal medium is also consistent with a hypothesis of co-ordinated pro-
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osteogenic changes in IGF axis activity during osteogenic differentiation of DPC cultures. As 
a caveat to these conclusions, it is worthy of note that STC2 mRNA expression does not 
alter between basal and osteogenic conditions (Fig 23). Although we have no ready 
explanation for this, as for PAPP-A some consideration should be given to whether the 
STC2 ELISA is able to detect both free and complexed STC2.  We provide limited evidence 
that in IP/WB experiments that STC2 protein is present at higher concentrations in basal 
compared to osteogenic media (Fig 27). Comparing the concentrations of PAPP-A and 
STC2 under basal or osteogenic conditions indicates that the molar PAPP-A: STC2 ratio is 
close to 1 under basal conditions and 10 under osteogenic conditions (Appendix Table II). 
Although the stoichiometry of the covalent PAPP-A: STC2 complex is 2:2, we find that even 
under basal conditions, IGFBP-4 is proteolysed. This indicates that an active fraction of 
PAPP-A exists in basal CM and suggests that covalent complex formation between PAPP-A 
and STC2 might be a regulated process. In order to confirm that endogenous PAPP-A 
present in DPC CM is able to form a complex with STC2, we conducted the experiments 
described in Fig 25-27. IP and WB of basal and osteogenic CM with anti-PAPP-A antibodies 
showed the presence of slowly migrating 500 and 400 kDa species. The former of these 
represents endogenous PAPP-A: STC2 complexes and the latter uncomplexed PAPP-A. 
Addition of rSTC2 to basal CM decreased the intensity of the free PAPP-A species 
suggesting increased association of PAPP-A with added STC2 (Fig 26). This effect was also 
seen in osteogenic CM along with an increase in intensity of the more slowly migrating 
PAPP-A: STC2 complex. These data suggest that in DPC CM endogenous PAPP-A and 
STC2 can form complexes and that PAPP-A activity may be regulated by this interaction. 
Finally, to confirm the presence of endogenous STC2 in high-molecular weight complexes in 
DPC CM we carried out IP/WB experiments with anti-STC2 antibodies as described in Fig 
27. Under these conditions a substantial proportion of STC2 is present in the form of high-
molecular weight complexes in both basal and osteogenic conditions – Mr ~ 500 kDa.  This 
provides further evidence that endogenous PAPP-A:STC2 complexes exist in medium 
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conditioned by DPC cultures under both basal and osteogenic conditions and may represent 
a mechanism by which PAPP-A and therefore IGFBP-4 proteolysis may be regulated in 
these culture conditions. There are very little data on the formation of PAPP-A: STC2 
complexes by cell cultures. In one study primary cultures of human aortic smooth muscle 
cells were shown to secrete both PAPP-A and STC2 into conditioned medium [255]. In these 
cells the concentration of PAPP-A reached 400 ng/ml which is approximately 10-20 fold 
higher than we found for DPC conditioned medium (note however as conditioned medium 
volume was not reported by Steffensen et al direct comparisons are difficult). 
Notwithstanding this in aortic SMCs it appeared that all of the endogenous PAPP-A was 
associated with co-secreted STC2 such that no IGFBP-4 proteolytic activity was evident in 
aortic SMC conditioned medium. In contrast in both basal and osteogenically DPC 
conditioned medium IGFBP-4 proteolysis was clearly evident. This was supported by the 
presence of uncomplexed PAPP-A in DPC conditioned medium. In addition, the increased 
molar ratio of PAPP-A: STC2 under osteogenic conditions compare to basal conditions (10:1 
see Appendix Table II) is consistent with the regulation of PAPP-A activity by complexation 
with STC2. 
 In conclusion, we have shown that co-ordinated transcriptional and post-transcriptional 
changes occur in the IGF axis which may facilitate the osteogenic action of IGFs during 
differentiation of these cells. These include increased IGF-II expression; increased PAPP-A 
expression; decreased STC2 expression; the presence of STC2: PAPP-A heterodimers 
presenting a potential regulatory action for PAPP-A. These changes culminate in increased 
IGFBP-4 proteolysis (the most abundant IGFBP expressed by DPCs), potentially allowing 
increased access of local and systemic IGFs to cell surface IGF1R which is abundantly 
expressed in these cells. We believe our data may be relevant in those situations where 
bone tissue formation and maintenance may be compromised (e.g. osteoporosis) and may 
provide new molecular targets for anti-osteopenic therapeutic strategies. 
116 
 
 
Whereas this thesis focuses on the PAPP-A induced cleavage of IGFBP-4 as a means of 
regulating IGF activity in DPCs, it should be noted that IGF-independent effects of IGFBP-4 
have also been described. For example, in ovarian granulosa cell cultures IGFBP-4 inhibited 
steroidogenesis in an IGF-independent manner [264]. Similarly, IGFBP-4 was shown to be 
an IGF-independent cardiogenic growth factor both in vitro and in vivo[265]. These studies 
used a range of techniques – antibody blockage of IGF-1R, sequestration of IGFs with 
heterologous IGFBPs, non-IGF binding IGFBP-4 analogues and knock down of IGFBP-4 to 
dissect out IGF-independent effects of IGFBP-4. It would be interesting in future studies to 
use one or more of these techniques to examine IGF-independent effects of IGFBP-4. 
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Chapter 6 General Discussion 
 
6.1 General Discussion 
This thesis describes studies with differentiated hDPCs. These cells have been extensively 
characterized during differentiation to an osteogenic phenotype [1, 19-21].Our laboratories 
have previously confirmed the characteristics of these differentiating cells [H. Alkharobi 
PhD thesis]. 
Compared to our stated Aims and Objectives (Section 1.7) we have shown 
• expression of all components of the IGF axis (except IGF-I and IGFBP-1) in DPC 
grown under basal and osteogenic conditions 
• IGFBP protein concentrations in DPC conditioned medium closely follow mRNA levels 
• IGFBP-4 is the most abundant IGFBP in both basal and osteogenic DPCs and levels 
are not altered between basal and osteogenic cultures 
• IGF-I and IGF-II stimulate osteogenic differentiation in DPC in a dose-dependent 
manner 
• IGFBP-4 and -5 inhibit IGF-I stimulated osteogenic differentiation in DPCs 
• IGFBP-4 proteolysis is enhanced under osteogenic conditions 
• PAPP-A is the sole IGFBP-4 protease in DPC conditioned medium and its 
concentration is increased under osteogenic conditions 
• IGF-II concentrations are increased under osteogenic conditions 
• STC2 concentrations are decreased under osteogenic conditions 
• PAPP-A: STC2 complexes can be identified in DPC conditioned medium 
We suggest that these changes in IGF axis expression and activity represent a novel IGF 
axis signature associated with pro-osteogenic action in DPCs. A diagrammatic summary of 
the main findings in this thesis is presented in Fig 28. 
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PAPP-A: STC2 
IGFBP-4 
proteolysis  
IGF activity  
Figure 28 A summary of the experimental findings presented 
in the current work. 
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Although our study focusses on a potential role for the IGF: PAPP-A axis in the 
differentiation of DPCs there is a limited literature which suggests a role for PAPP-A in the 
differentiation of other cell types. For example during establishment of the human placenta 
PAPP-A mRNA and protein expression are increased 19- and 8-fold respectively during the 
terminal differentiation of human cytotrophoblast cells to the multinucleated invasive 
syncytiotrophoblast phenotype in vitro [266]. Similarly the addition of exogenous PAPP-A or 
over-expression of the protease in the C2C12 mouse myoblast cell line increased cell 
proliferation but also differentiation into myotube structures[267]. In this instance the authors 
suggested that the effects of PAPP-A were mediated through proteolysis of IGFBP-2 (see 
Section 1.4.3 p.31). Finally, over expression of PAPP-A in the HC11 mouse mammary cell 
line increased differentiation (as demonstrated by increased β-casein expression) to a 
lactating phenotype [268]. Note however that in this study exogenous PAPP-A was without 
effect and this phenomenon requires further investigation.  
The PAPP-A/IGFBP-4 axis has also been proposed to play a role in other 
physiological/pathological biological systems. The role of this molecular axis in the 
atherosclerotic and cardiovascular disease has been reported. Therefore PAPP-A is 
expressed by both vascular smooth muscle cells (VMSCs) and endothelial cells in 
atherosclerotic plaques [269]. This has led to the hypothesis that increased IGF activity 
contributes to the formation of atherosclerotic plaques. However, the role of enhanced 
PAPP-A in the development of such plaques is controversial with studies reporting both 
protective [270-272] and deleterious [273] effects on plaque formation. Recent sophisticated 
transgenic approaches have suggested a role for cell surface PAPP-A activity in both the 
development and destabilisation of atherosclerotic plaques [274, 275]. 
Although not addressed in the current study, there is increasing evidence for a role of PAPP-
A as a tumour promoter. Theoretically this is founded on the action of PAPP-A as an IGFBP 
protease releasing previously IGFBP bound IGFs into the vicinity of tumour cells and/or 
tissues -the implication of this being a higher paracrine concentration of mitogenic IGFs to 
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drive tumour cell propagation.  For example Mansfield et al reported that PAPP-A was 
expressed in breast cancers displaying an aggressive phenotype [276]. Similarly in a 
transgenic mouse model the development of mammary tumours was associated with 
increased PAPP-A expression and IGFBP-4 proteolysis [277] and a subsequent report 
suggested that such effects may be mediated by p53 based regulation of PAPP-A 
expression [278].In agreement with this a very recent report showed that an engineered 
PAP-A resistant IGFBP-4 inhibited the invasive potential of mouse mammary carcinoma 
cells [279].  It should be noted however that there is some contradictory data with reports 
that PAPP-A was epigenetically silenced in breast cancer precursor lesions and that this 
lead to down regulation of PAPP-A expression and the development of more invasive 
tumours [280]. We would re-iterate at this point that PAPP-A presents as an attractive target 
for anti-tumour therapy (see p.41 Section 1.5.2) further research into off target effects is 
required. 
Another recent study has shown the upregulation of PAPP-A on the surface of Ewing’s 
sarcoma cells and may be associated with evasion of immune mechanisms associated with 
tumour suppression [281]. This has led to the suggestion that PAPP-A may represent a 
therapeutic target in this tumour perhaps through activation of immunological defence 
mechanisms [282].   A recent review has outlined the current literature in the area of PAPP-
A and tumour biology [195].  
There is a limited literature describing the role of the IGF axis in the development and 
function of dental tissues. Early studies reported the stimulation of proliferation and 
extracellular matrix secretion by dental pulp-derived fibroblasts following IGF-I treatment 
[228], leading these authors to suggest that IGF-I, together with other polypeptide growth 
factors (PDGF, EGF, bFGF), may play a role in differentiation of these cells. These findings 
have been independently confirmed, although some variation in growth factor activity related 
to cell passage number has been reported [283]. An elegant study used in situ hybridisation 
to demonstrate developmental stage-dependent expression of IGF-I in the continually 
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erupting rat incisor model [236] and, in related studies, GH and IGF-I acting independently 
were reported to increase expression of bone morphogenetic protein (BMP)-2 and -4 by up 
to fivefold, suggesting that the osteogenic activities of both hormones may be mediated by 
these BMPs [229]. Onishi et al. have shown that IGF-I and -2 increased ALP activity and 
proliferation in canine dental pulp-derived cells. Insulin was also effective but only at higher 
doses than IGFs [233], consistent with cross-reactivity but lower affinity at the IGF-1R (see 
above). Amongst other highly expressed genes of the IGF axis in dental pulp are IGF-2 [243] 
and IGFIR [284]. In an important study, high levels of IGF-2 secretion were reported during 
the osteogenic differentiation of human dental pulp-derived fibroblasts [238], and the same 
study indicated an increase in IGF-IR and IGFBP-3 expression during osteogenic 
differentiation of these cells. Whether any of these changes in gene expression are causally 
associated with the process of dental pulp stem cell differentiation remains to be established. 
However, our preliminary data suggest an increase in IGF-1 and IGF-1R expression after 3 
weeks osteogenic differentiation of dental pulp-derived stromal cells (unpublished 
observations). A subsequent detailed immunohistochemical examination of IGF axis 
components in other dental structures reported the presence of IGF-I and -2 together with all 
six IGFBPs in the extracellular matrix (ECM) of the periodontal ligament, and the presence of 
IGF-IR on the surface of periodontal ligament- derived fibroblasts. These authors similarly 
concluded that the location of specific IGF axis members within dental structures may reflect 
distinct roles for each of these genes during processes of tooth development [285]. In a 
further extremely detailed in situ hybridisation/immunohistochemical analysis of IGF axis 
expression during the life cycle of differentiating ameloblasts, very strong reactivity for IGF-I, 
IGF-2, IGF-IR and IGF-2R was evident at the outer enamel epithelial layer towards the 
apical loop in the continuingly erupting rat incisor model. In pulp-facing ameloblasts, 
reactivity towards these IGF axis genes was somewhat reduced. This indicates once again 
position-specific expression of IGF axis components, and suggests the importance of this 
axis in the development of dental tissues [235, 286], IGFBP-5 is also up-regulated during 
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osteogenic differentiation of dental pulp stem cells [245, 287]. We and others have 
suggested a role for this protein in the differentiation of other cell types [288], and the role of 
this IGF binding protein in the differentiation of dental pulp cells warrants further 
investigation. Finally, an interesting recent study using stem cells isolated from apical 
papillae reported that IGF-I stimulated cell proliferation, ALP expression and mineralisation 
activity in these cells. Interestingly, expression of odontogenic markers (dentin sialoprotein 
and dentin sialophosphoprotein) was down regulated. This argues for a bias in IGF-I action 
towards bone tissue formation and away from chondrogenic structures in this particular 
tissue niche [289]. 
6.2 Limitations of current study 
 We were not able to resolve the issue of increased PAPP-A protein and activity in 
osteogenic DPC conditioned medium in the face of unaltered PAPP-A mRNA levels in basal 
v osteogenic conditions (Fig 21 and Section 5.7) and this is an area of ongoing investigation. 
As PAPP-A is known to associate with glycosaminoglycan (GAG) components of the cell 
membrane [176] we attempted to test the hypothesis that PAPP-A was differentially released 
from the membranes of DPCs undergoing differentiation resulting in higher protein 
concentrations in osteogenic conditioned medium. However, using a FACS based 
methodology we were unable to identify membrane bound PAPP-A and this area requires 
further investigation. Similar issues surround mRNA and protein assay for STC2 (Figs 
23&24). In this instance it may be that STC2 protein levels are subject to selective post-
translational control under osteogenic conditions although in section 5.7 we also highlight 
technical issues surrounding assays for STC2 (and PAPP-A) in the presence of PAPP-
A:STC2 complexes. 
In the context of DPC differentiation it is important to note dexamethasone stimulates PAPP-
A activity [200].  Therefore, PAPP-A activity should be re-examined under dexamethasone-
free osteogenic conditions to establish that changes in PAPP-A expression and activity are 
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the consequences of differentiation itself and not solely due to the effect of the synthetic 
glucocorticoid.  
We did not investigate expression of insulin receptor (IR) A- or B (IR-A or IR-B) in DPCs .In 
the light of the expression of IGF-II by DPCs this may be a significant omission as IGF-II is 
able to bind IR-A isoform with high affinity and IGF-I binds with high affinity hybrid receptors 
containing an IGF1R dimer in association with an IR-A dimer [290]As both interactions are 
biologically productive this is an area which requires further investigation. Clearly there are 
limitations in extrapolation from in vitro studies to in vivo biological systems. Perhaps the 
most important amongst these in the IGF axis is the recreation of an appropriate matrix 
environment in vitro. As tissue matrix is known to play a crucial role in IGF axis activity (see 
Section 1.3.1) this is a clear limitation of many studies. In DPCs, which secrete a specific 
matrix during osteogenic differentiation (see Section 1.2.3) this is a particular concern in our 
tissue culture model and future studies should take full account of this fact.  
6.3 Future Work 
In addition to the issues raised above and although we clearly demonstrated increased 
IGFBP-4 proteolysis under osteogenic conditions in DPCs there are now commercially 
available ELISAs for N-terminal and C-terminal IGFBP-4 fragments [291].It may be 
worthwhile to obtain more accurate quantitative data on IGFBP-4 proteolysis using this 
technique. In addition IGFBP-4 is N-glycosylated [292] and there is evidence that PAPP-A 
activity may be affected by the glycosylation status of IGFBP-4[293]. It would be interesting 
to investigate whether this paradigm operated in DPCs. Further work is required to establish 
causality within our experimental model. In our view much could be gained by the 
establishment of transient and stable DPC cell lines transfected with osteogenic promoter 
constructs containing a convenient read out of activation (e.g. luciferase). Knock out and 
over-expression of some of the candidate genes identified in this study (particularly PAPP-A 
and STC2) could be used to examine potential roles for these proteins in the osteogenic 
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process. Some interesting recent work has reported some epigenetic mechanisms 
associated with IGF axis function in periodontal ligament-derived stem cells (PDLSCs) 
whereby the expression of IGFBP-5 is regulated by the methylation status of histone K27. 
Therefore down-regulation of the histone demethylase KDM6B is associated with increased 
K27 tri-methylation (K27Me3) in the IGFBP-5 promoter [294] and subsequent decreased 
IGFBP-5 expression. As the same group demonstrated that IGFBP-5 had positive 
stimulatory effects on the osteogenic differentiation of PDLSCs [295] these findings suggest 
an epigenetic route by which the IGF axis may be manipulated to enhance differentiation 
potential of dental tissue derived stem cells. However, whether such mechanisms exist for 
the PAPP-A: IGFBP-4 axis discussed in this thesis is unknown but is worthy of further 
investigation. 
6.4 Final Conclusions 
Under osteogenic conditions, increased expression of IGF-II and PAPP-A, together with 
decreased STC2 expression lead to a putative decrease in inhibitory PAPP-A: STC2 
complex formation. The resulting increase in PAPP-A activity causes increased IGFBP-4 
proteolysis which has the potential to increase pericellular IGF activity thus stimulating 
osteogenesis in DPCs. 
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Supplementary Table 1 TaqMan expression assay identifiers for genes analysed in 
current study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Name 
TaqMan®Gene 
expression 
assay identifier 
GAPDH 
Hs99999905_m1 
ALPL Hs01029144_m1 
OCN Hs00609452_g1 
Runx2 Hs00231692_m1 
IGF-I Hs01547656_m1 
IGF-II Hs04188276_m1 
IGF1R Hs00609566_m1 
IGF2 R Hs00974474_m1 
IGFBP 1 Hs00236877_m1 
IGFBP 2 Hs01040719_m1 
IGFBP 3 Hs00426289_m1 
IGFBP4 Hs01057900_m1 
IGFBP 5 Hs00181213_m1 
IGFBP 6 
Hs00181853_m1 
 
PAPP-A Hs01032307_m1 
STC1 Hs00174970_ m1 
STC2 Hs01063215 _m1 
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Supplementary Table 2 Molar concentrations of selected IGF axis components in 
basal and osteogenic conditioned medium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyte Basal (pM) Osteo (pM) 
IGF-II 92 ± 22 863 ± 37 
IGFBP-4 3072 ± 257 3180 ± 111 
IGFBP-5 542 ± 136 346 ± 48 
PAPP-A 47 ± 2.5 92 ± 4 
STC2 49 ± 24 8.5 ± 7.2 
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